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Mucolipidosis type IV (MLIV) is a lysosomal storage disease resulting from mutations in 
the gene MCOLN1, which codes for a transient receptor potential family ion channel TRPML1 
(Mucolipin-1). MLIV has an early onset and is characterized by developmental delays, motor 
and cognitive deficiencies, gastric abnormalities, retinal degeneration and corneal cloudiness. 
The degenerative aspects of MLIV have been attributed to cell death, whose mechanisms remain 
to be delineated in MLIV and most other lysosomal storage diseases. The function of TRPML1 
is still not completely understood in the cell.  In order to address the function of this channel as 
well as the consequences of its loss, we have studied TRPML1 and a closely related channel 
TRPML3 using proteomic, transcriptional, and ion channel activity assays.  Structure/function 
analyses of TRPML (Mucolipin) channels revealed that the closely related TRPML3 channel 
conducts K+, Na2+, Ca2+, and Fe2+, but does not conduct transition metals such as Cu2+ and Co2+.  
The permeability of the channel can be disrupted by mutations to the pore domain and a 
constitutively active channel mutation abolishes transition metal block of both TRPML1 and 
TRPML3. The similarities in TRPML sequence and the activity of the constitutively active 
mutants suggests that these channels may share similar activity profiles, which supports previous 
reports that TRPML1 may function to regulate lysosomal Ca2+ and Fe2+ in order to promote 
proper lysosomal fission/fusion events and function.  Our proteomic and transcriptional analyses 
reveal that acute downregulation of TRPML1 results in apoptosis in a cathepsin B and Bax 
STUDY OF TRPML CHANNELS REVEALS INSIGHT INTO ENDOCYTIC 
MALFUNCTION, ORGANELLE CROSSTALK, AND THE ACTIVATION OF PRO-
APOPTOTIC PATHWAYS 
 
 Grace Ann Colletti, PhD 
University of Pittsburgh, 2011
 
 v 
dependent manner.  This is the first evidence that acute TRPML1 loss is linked to apoptosis and 
my work provides a preliminary mechanism for this process.  Furthermore, TRPML1 loss results 
in increased NFκB levels as well as altered transcription of genes outside the previously 
identified lysosomal gene expression network.  This suggests that loss of TRPML1 results in 
cellular changes that affect downstream transcriptional targets and induces cellular responses, 
such as apoptosis.  Taken together, these data shed light on the importance of TRPML1 function 
and may help us understand the cellular role of this channel and how its loss results in cell death. 
 
 
 
 vi 
TABLE OF CONTENTS 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 OVERVIEW ......................................................................................................... 1 
1.2 LYSOSOMES ...................................................................................................... 4 
1.2.1 Lysosomal function and formation ................................................................ 5 
1.2.2 Synthesis and trafficking of lysosomal proteins............................................ 9 
1.2.3 Lysosomal storage disorders......................................................................... 14 
1.2.4 Cathepsin-induced Apoptosis ....................................................................... 18 
1.3 TRPML1 ............................................................................................................. 20 
1.3.1 TRPML1 characterization ............................................................................ 21 
1.3.2 Proposed Models of TRPML1 Function ...................................................... 22 
1.3.3 New techniques of studying TRPML1 function .......................................... 24 
1.3.4 MLIV .............................................................................................................. 27 
1.3.5 Transition metal toxicity and TRPML1 ...................................................... 28 
1.4 GOALS OF THIS DISSERTATION ............................................................... 32 
2.0 CATHEPSIN B MEDIATED APOPTOSIS IN TRPML1 DEFICIENT CELLS 33 
2.1 ABSTRACT........................................................................................................ 33 
2.2 INTRODUCTION ............................................................................................. 34 
2.3 EXPERIMENTAL PROCEDURES ................................................................ 35 
 vii 
2.4 RESULTS ........................................................................................................... 40 
2.4.1 TRPML1 and PPT1 KD ................................................................................ 40 
2.4.2 CatB buildup in TRPML1 KD cells ............................................................. 42 
2.4.3 CatB release in TRPML1 KD cells .............................................................. 49 
2.4.4 CatB and apoptosis in TRPML1 deficient cells .......................................... 54 
2.5 DISCUSSION ..................................................................................................... 56 
2.6 ACKNOWLEDGEMENTS .............................................................................. 59 
3.0 ACUTE DOWNREGULATION OF LYSOSOMAL GENES SPECIFICALLY 
AFFECTS TRANSCRIPTION OF GENES OUTSIDE THE “CLEAR” NETWORK ....... 60 
3.1 ABSTRACT........................................................................................................ 60 
3.2 INTRODUCTION ............................................................................................. 61 
3.3 EXPERIMENTAL PROCEDURES ................................................................ 64 
3.4 RESULTS ........................................................................................................... 65 
3.4.1 Microarrays show specific gene changes in TRPML1 and PPT1 KD ...... 65 
3.4.2 Regulatory analysis of TRPML1 KD suggests that changes in gene 
expression may be regulated by specific transcription factors .............................. 67 
3.4.3 NFκB is upregulated in TRPML1 KD cells and may regulate 
transcriptional changes .............................................................................................. 69 
3.4.4 Comparison of TRPML1 and PPT1 KD reveals common TFs associated 
with altered genes. ...................................................................................................... 70 
3.5 DISCUSSION ..................................................................................................... 71 
3.6 ACKNOWLEDGEMENTS .............................................................................. 73 
4.0 TRPML3 BLOCK BY TRANSITION METALS ................................................... 74 
 viii 
4.1 ABSTRACT........................................................................................................ 74 
4.2 INTRODUCTION ............................................................................................. 75 
4.3 EXPERIMENTAL PROCEDURES ................................................................ 78 
4.4 RESULTS ........................................................................................................... 80 
4.4.1 TRPML3 is activated by PI(3,5)P2 ............................................................... 80 
4.4.2 TRPML3 is blocked by transition metals .................................................... 83 
4.4.3 Significance of TRPML block by transition metals. .................................. 88 
4.5 DISCUSSION ..................................................................................................... 95 
4.6 ACKNOWLEDGEMENTS .............................................................................. 96 
5.0 CONCLUSIONS AND FUTURE DIRECTIONS ................................................... 97 
APPENDIX A ............................................................................................................................ 103 
APPENDIX B ............................................................................................................................ 107 
BIBLIOGRAPHY ..................................................................................................................... 116 
 ix 
 LIST OF TABLES 
Table 1.1  Models of TRPML1 loss and the resulting phenotypes ............................................... 24 
Table.A.1 Gene candidates from TRPML1 KD microarray ....................................................... 103 
Table A.2  Gene candidates for PPT1 KD microarray ............................................................... 104 
 x 
LIST OF FIGURES 
Figure 1.1 Model of biosynthetic trafficking of lysosomal hydrolytic enzymes .......................... 11 
Figure 1.2. Mitochondrial fragmentation in storage diseases due to defects in autophagy may 
promote proapoptotic pathways. ................................................................................................... 31 
Figure 2.1 siRNA-mediated downregulation of TRPML1 and PPT1 result in decreased mRNA 
and protein levels and recapitulate a storage defect phenotype. ................................................... 41 
Figure 2.2 TRPML1 KD and PPT1 KD specifically alter steady state protein levels of CatB, 
LAL, and LAMP-1........................................................................................................................ 43 
Figure 2.3 Increased levels of CatB and decreases LAL levels are TRPML1 specific and not due 
to general endocytic disruption. .................................................................................................... 45 
Figure 2.4 TFEB regulated lysosomal genes and TFEB levels are unaltered in acute TRPML1 
and PPT1 KD cells. ....................................................................................................................... 48 
Figure 2.5 Levels of CatB activity and secreted proCatB are elevated in TRPML1 KD cells. .... 51 
Figure 2.6 TRPML1 KD results in high levels of cytosolic and membrane associated CatB. ..... 53 
Figure 2.7 TRPML1 KD results in cell death via Bax and CatB dependent mechanism. ............ 56 
Figure 3.1 Candidate genes CD83 and LYPLA1 are downregulated in TRPML1 but not PPT1 KD 
cells. .............................................................................................................................................. 68 
Figure 3.2 Analysis of TRPML1 KD candidate genes reveals common subset of TFs which may 
regulate candidate gene expression, including NFκB. .................................................................. 69 
 xi 
Figure 3.3 Comparison of TFs associated with candidate genes in TRPML1 and PPT1 KD ...... 71 
Figure 4.1 TRPML3 activation by PI(3,5)P2................................................................................ 82 
Figure 4.2 TRPML3 block by transition metals. .......................................................................... 84 
Figure 4.3 The Va mutants and transition metals. ........................................................................ 86 
Figure 4.4 Cysteine residues in TRPML3 and block by transition metals. .................................. 88 
Figure 4.5 Ultrastructural comparison of TRPML KD and metal treated cells. ........................... 91 
Figure 4.6 Inclusion types in metal treated and siRNA transfected HeLa cells. .......................... 92 
Figure 4.7 Inclusion profiles in metal treated and TRPML siRNA transfected HeLa cells. ........ 94 
Figure 5.1 Model representing changes in TRPML1 KD cells and how these may contribute to 
cellular malfunction. ................................................................................................................... 100 
Figure B.1 Analysis of mutants reveals inactivating mutations in the pore and S3 domains of 
TRPML3. .................................................................................................................................... 110 
Figure B.2 Sensitivity of Va TRPML3 and TRPML1 mutants to Cu2+ ...................................... 112 
Figure B.3. TRPML3 KD results in similar cellular changes as TRPML1 KD ......................... 114 
 
 xii 
PREFACE 
I would like to thank many people who have helped me with this work throughout my 
graduate career.  First, I would like to thank my advisor, Kirill Kiselyov for his unrelenting 
guidance and trust.  He has helped me through the hardest parts of this dissertation work and 
always reminded me of my capabilities, pushing me to accomplish what he knew I was capable 
of.   Kirill provided the perfect balance of guidance as well as independence, allowing me to 
pursue questions and hypotheses which helped me grow as a scientist.  He is a wonderful advisor 
as well as friend and I am very thankful to have him as my graduate mentor.   
I would also like to thank the members of my lab.  Although labs change over the years, I 
was lucky enough to be accompanied throughout my graduate career by wonderful, supportive 
lab mates.  I was able to mentor many of them enriching my experience as a teacher as well as 
graduate student.  In particular, I’d like to thank Emina Hodzic, Ira Kukic, Youssef Rbaibi, and 
Jeffrey Lee for their friendship and optimism throughout my years here.  I would also like to 
thank all of the past members who have contributed to this work, whether through experimental 
help, discussion, or just support and guidance! 
I would like to thank my thesis committee:  Dr. Jeffrey Hildebrand, Dr. William 
Saunders, Dr. Michael Grabe, and Dr. Ora A. Weisz for all of their help!  They really kept me on 
track and helped me work through difficult times in my work.  Thank you for your criticism, 
support, and guidance which made me a better scientist!  I would also like to extend my thanks 
 xiii 
to members of the Weisz lab including Jennifer Bruns and Mark T. Miedel for their collaboration 
on this project.   
I would not be as happy and as successful if it was not for my friends and family.  First, I 
need to thank my undergraduate research mentor, Dr. Jonathan Karp.  Jonathan has not only been 
a wonderful advisor but also a great friend who inspired me to pursue my interest in science and 
has always reminded me why I love what I do!  Next I want to thank my family, especially my 
mom and dad.  They have also always supported my work and I thank them for all of their love 
and guidance! I definitely could not have gotten to this point without them and I am so lucky that 
they are always there for support!  And finally, I’d like to thank my fiancé, Matthew Farber. Matt 
was always there to encourage me, push me forward, and make me laugh (especially when I 
desperately needed one!).  He has helped me stay focused and reminded me of what is important.  
We wrote our dissertations during the same time, and although most might think this could hurt a 
couple, it has definitely made us stronger.  He is my favorite person to be around so writing with 
him just made the process that much easier.  So Matt, thank you for all your help and I love you!   
 
 
 
 
 1 
1.0  INTRODUCTION 
1.1 OVERVIEW 
TRPML1 is a member of the Transient Receptor Potential (TRP) family of ion channels. 
Unlike most TRP channels, TRPML1 and its relative TRPML2 and TRPML3 primarily reside in 
the membranes of the endocytic pathway (1-6). TRPML1 localizes to the lower portions of the 
endocytic pathway (late endosomes and lysosomes), due to the presence of a lysosomal 
localization tag on its N-terminal (5). TRPML1 was shown to be an inwardly rectifying cation 
channel (ions flow out of the lysosomal compartment), whose activity is potentiated by PI(3,5)P2 
and by low, typically lysosomal, levels of pH (7, 8). TRPML1 activation by PI(3,5)P2, a lipid 
predominantly found in late endosomes and lysosomes, provides physiological context for its 
localization suggesting that it is either activated by delivery to the lysosomes or it serves as a 
proximity sensor in lysosomes and late endosomes (9). TRPML1 was suggested to regulate 
fusion/fission of vesicles in the endocytic pathway, and/or some aspect of lysosomal ion 
homeostasis such as pH or Fe2+ content (7, 10).  
TRPML1 loss is due to mutations in the gene MCOLN1 resulting in the rare lysosomal 
storage disease Mucolipidosis type IV (MLIV) (2, 11). The disease is associated with the buildup 
of storage bodies and has a profound neurodegenerative profile, which, in mouse models, has 
been linked to retinal degeneration and demyelination of corpus callosum, deep layer neocortex, 
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and cerebellar white matter tracts (12, 13). As with most lysosomal storage diseases, the 
mechanisms of cell death in MLIV are unclear. It was previously suggested that lysosomal 
deficiencies in MLIV and, perhaps, other storage diseases, lead to autophagic deficits and 
buildup of effete mitochondria, which may expose cells to pro-apoptotic effects of stimulation 
(14, 15). Nonetheless, the selectivity of cellular loss in storage diseases remains puzzling. We 
believe that the key to identifying the cell death pathway in MLIV lies in deconstructing the 
early events accompanying the loss of TRPML1 as well as understanding the function and 
activity of TRPML1 itself. Previous studies in patients’ cells have provided conflicting and often 
convoluted data likely due to the contribution of secondary effects due to chronic accumulation 
of storage material.  This accumulation of lysosomal substrates may have little to do with the 
core cause of the disease; therefore, a system lacking secondary defects is needed to understand 
the underlying effects of TRPML1 loss. Furthermore, human skin fibroblasts from MLIV 
patients, predominantly used in experiments, perform fairly well in culture suggesting that the 
mechanisms responsible for cell death in MLIV are suppressed and/or do not fully manifest in 
these cells.  
To delineate the early events associated with the loss of TRPML1 we used siRNA 
mediated knockdown (KD) to acutely downregulate TRPML1 in HeLa cells. A KD of palmitoyl-
protein thioesterase 1 (PPT1), an enzyme mutated in another lysosomal storage disease, Infantile 
Neuronal Lipofuscinosis, was used as a comparative control (16, 17).  We show that TRPML1 
loss specifically causes, within 48 hours after KD, a cytoplasmic buildup of the lysosomal 
protease CatB and Bax/CatB dependent apoptosis (Section 2).  These results illustrate, for the 
first time, the early events leading to cell death in TRPML1 deficient cells.   
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Interestingly, acute TRPML1 KD, but not PPT1 KD, induced NFκB upregulation and 
altered expression of NFκB regulated genes (Section 3).  The genes altered by TRPML1 KD 
were not part of a previously identified lysosomal gene network, suggesting that these changes 
are not due to the same lysosomal dysfunction which activates the lysosomal network (18) but 
rather to changes caused by TRPML1 KD, possibly at the protein level.  Further work will be 
needed to delineate the pathways that result in NFκB upregulation and transcriptional changes. 
The final portion of this work focuses on characterizing the activity of mucolipin 
channels and how they are affected by transition metals.  Proper transport of transition metals 
from endocytic compartments to the cytosol has been shown to be critical for proper cell 
function and is necessary to prevent destructive ROS production.  Therefore the permeability of 
several transition metals was evaluated in mucolipin channels.  To do this, we performed 
structure/function studies using whole cell patch clamp analysis.  TRPML1 does not show 
activity when using whole cell patch clamp analysis, as it is not targeted to the plasma membrane 
(5, 19).  However, its close relative TRPML3 does localize to the plasma membrane when 
overexpressed (8, 20-26).  Therefore we used TRPML3 as a model to study mucolipin activity 
and transition metal block.  We tested the conductance of several ions including Na+, K+, Ca2+, 
and several transition metals such as Co2+, Cu2+, Ni2+, Fe2+, and Zn2+  both in wildtype and 
mutated forms of the channel.  Mutations were made in conserved residues within the pore 
domain and surrounding residues of the channel. We report that TRPML3 conducts Na+, K+, 
Ca2+, and Fe2+ but is blocked by micromolar concentrations of Co2+, Cu2+, Ni2+ and Zn2+. A 
cysteine residue near the channel pore contributes to TRPML3’s sensitivity to transition metals. 
The varitint-waddler (Va) TRPML3 spontaneously active mutant is insensitive to transition 
metal block. Interestingly the Va mutation in TRPML1 results in TRPML1 plasma membrane 
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expression which can be detected by whole cell patch clamp analysis.  The Va TRPML1 channel 
conducts ions similarly to the TRPML3 Va mutant.  Both mutants are resistant to transition metal 
block showing that these channels may share common conductance profiles.     
This dissertation is divided into 4 sections: 1) background information, 2-3) the effects of 
TRPML1 downregulation including transcriptional changes and apoptosis, 4) the 
characterization of mucolipin channel activity and the effect of transition metal toxicity on cells 
and the possible role of mucolipins.  The following introduction provides a review of lysosomes, 
cathepsin-mediated apoptosis, TRPML1, MLIV, and the role of the endocytic pathway in 
transition metal toxicity. 
 
1.2 LYSOSOMES 
The discovery of lysosomes appears to have arisen from a laboratory mishap.  Christian 
De Duve’s lab performed tissue fractionation through differential centrifugation and tested each 
fraction for acid phosphatase activity.  Interestingy, another sample set was left in the refrigerator 
for 5 days and then assayed for acid phosphatase activity.  The refrigerated samples showed 
increased amounts of acid phosphatase activity.  This lead De Duve’s group to speculate that the 
enzyme was bound in a membrane compartment (originally thought to be mitochondrial) and 
that over time, the enzyme was liberated from the compartment (27).  Over the next several years 
De Duve and his colleagues characterized these membrane compartments calling them 
lysosomes due to their abundance of hydrolytic enzymes (28, 29).  Through lysosomal 
characterization, it has become clear that lysosomes are necessary for proper cell function, 
 5 
playing critical roles in substrate degradation, absorption of endocytosed material, and 
autophagy, a central housekeeping and survival function (30-35).   
Lysosomal hydrolases work in the specific pH environment of the lysosome, maintained 
through several channels and transporters; therefore, the regulation and maintanence of this 
lysosomal environment is critical for cell survival.  Several diseases are caused by the improper 
delivery or loss of function of both lysosomal transporters and hydrolytic enzymes.  These 
“lysosomal storage disorders” result in severe neurodegenerative and motor defects, highlighting 
the importance of proper lysosomal activity.  Therefore it is necessary that lysosomal 
components are both functional and properly delivered to this organelle.  The following sections 
will discuss lysosomal formation and function, the biosynthesis of lysosomal proteins, and 
lysosomal-related diseases.   
1.2.1 Lysosomal function and formation  
Lysosomes function at deep levels of the endocytic pathway degrading substrates from 
late endosomes, autophagosomes, and chaperone-mediated autophagy as well as expelling 
nutrients into the extracellular environment through exocytosis. In this section, I will briefly 
discuss the role of lysosomes in autophagy, delivery of late endosomal substrates to the 
lysosome, and the regulation of the lysosomal environment.  
In autophagy, autophagosomes form double membranes around cytosolic domains, either 
containing proteins or effete organelles, such as dysfunctional, fragmented mitochondria.  
Autophagosomes are transported to lysosomes by dynein, either fusing to create a hybrid 
organelle called the “autolysosome” or briefly interacting with lysosomes to transfer autophagic 
substrates (36).  Upon fusion, the inner autophagosomal membrane enters the lysosomal lumen 
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where it is degraded, while the outer membrane temporarily fuses with the lysosomal membrane.  
Autophagosome degradation, but not docking, is dependent on proper lysosomal acidification 
(37).  The autophagic machinery, formation, and processes are well developed; therefore my 
work will focus on the interaction of autophagosomes with lysosomes. 
Similar to the outer membrane of the autophagosome, the late endosomal membrane is 
not degraded upon interaction with the lysosomes.  Rather, contents of late endosomes appear to 
be transferred to lysosomes through “kissing” events, formation of intervesicular tubules, and 
reversible fusion (38, 39).  “Kissing” refers to the brief interaction between the two 
compartments where the compartments do not completely fuse together.  Fusion results in a 
hybrid organelle containing both late endosome and lysosomal components.  Tubule formation 
between late endosomes and lysosomes appears to mediate content mixing before the fusion of 
hybrid compartments (38).  The late-endosome-lysosome hybrid organelle shares components of 
both organelles, is larger than either lysosomes or late endosomes alone, and is less dense than 
lysosomes (40).  Formation of these hybrid organelles is reversible, restoring the components of 
the two compartments. 
The fusion of lysosomes with autophagosomes and late endosomes is dependent on 
several factors, which coordinate the delivery, tethering, and fusion of these vesicles.  Several 
steps leading to lysosomal fusion with late endosomes and autophagosomes are conveyed by the 
GTPase Rab7, which has been shown to coordinate lysosomal fusion, autophagic maturation, 
and drive late endosome/lysosome perinuclear localization (41-44).    The Vps39 protein of the 
HOPS complex (composed of vacuolar protein sorting (VPS) proteins) is required for conversion 
of Rab5 (early endosomal GTPase) to Rab7, a necessary step in early endosomal maturation and 
has been shown to act as a Rab7 GEF (Guanine Nucleotide Exchange Factor) (45, 46).  Two 
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downstream effectors of Rab7, RILP and ORLP1, coordinate dynein/dynactin mediated minus-
end transport of late endosomes and lysosomes along microtubules (41, 47, 48). Therefore, Rab7 
seems to play multiple roles in the maturation and delivery of endosomal vesicles. 
The above mentioned HOPS complex is conserved between yeast and mammalian cells, 
and is thought to not only mediate Rab5 to Rab7 conversion, but to also act as a tether between 
late endosomes and lysosomes.  The HOPS complex is composed of VSP proteins 11, 16, 18, 33, 
39, and 41.  While Vsp39 displays Rab7 GEF activity, Vsp41 is thought to anchor the HOPS 
complex directly to Rab7 (49).  Rab7, in turn, mediates the interaction between the HOPS 
complex and SNARE complexes, discussed below (50). 
Fusion of the lysosome and late endosome vesicles is accomplished by the formation of a 
trans-SNARE complex (SNARE complexes are on opposing membranes) composed of 
Syntaxin7, Vti1b, Syntaxin8 and VAMP7 (51).  The specificity of this complex is conveyed 
through VAMP7, which is unique to lysosomal compartments (52).  Autophagic/lysosomal 
fusion is instead mediated by a SNARE complex consisting of Vti1b and VAMP8, independent 
of syntaxin 7/8 and VAMP7 involvement (53).  Lysosomal/late endosomal vesicle fusion is a 
Ca2+ driven event, mediated by intraorganelle Ca2+ stores, suggesting that late endocytic ion 
channels may play a role in regulating the fusion of these vesicles (54-56). 
Upon the delivery to the lysosome, substrates are broken down by specific hydrolytic 
enzymes.  These include proteases, peptidases, amylases, and lipases which function optimally in 
the acidic pH (~4.5-5.5) of the lysosome.  Some lysosomal hydrolases, such as Cathepsin B, are 
active in a wider pH range, allowing them to cleave proapoptotic cytosolic substrates, which will 
be discussed later (57-59).  However, most lysosomal enzymatic activity is dependent on the 
specific ionic environment of the lysosome, maintained through the activity of several membrane 
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channels and transporters. In addition, the acidity of the lysosome is necessary for proper sorting, 
fusion, and delivery to the lysosome (60-62).  This acidity is mainly regulated by the V-type 
ATPase H+ pump, which moves protons against the gradient into the lysosome, although other 
lysosomal transporters such as ClC-7 help regulate the activity of this pump (63, 64).  In addition 
to acidification, regulation of other lysosomal ion concentrations is critical for proper function.  
Channels and transporters found in the lysosomal membrane include TRPML1, discussed in 
depth in section 1.3, TPCN1/2, Slc11a2 (also called DMT1, NRAMP2), and ClC-7 (65-67).  The 
TPC channels were recently discovered to be Ca2+ release channels, activated by the messenger 
NAADP (68). Slc11a2 is a metal transporter which is responsible for moving substrate bound 
metals to the cytoplasm (65). ClC-7 was identified in the past several years as a lysosomal Cl-/H+ 
antiporter, which is necessary for proper lysosomal acidification (69, 70).  It is clear that 
maintaining the ionic environment of the lysosome is a tightly regulated process which is 
dependent on several components and is required for proper organelle function. 
It is important that cells maintain proper lysosomal levels in order to respond to the need 
for cellular digestion.  Formation or increase in lysosomes occurs through the synthesis and 
delivery of lysosomal components.  De novo lysosomal formation has not been shown; therefore 
it appears that the increase in lysosomal number results in addition of newly synthesized 
lysosomal components into the endocytic system, driving up lysosomal numbers.  It is well 
known that lysosome numbers change in response to specific lysosomal disruption (71, 72), 
suggesting that cells monitor the requirement for degradation and respond by altering lysosomal 
number and content.  Such a response requires a coordinated change in gene expression, which 
was shown recently through the discovery of a “degradation” gene network (18, 73).  Genes in 
this network contain the “CLEAR”, Coordinated Lysosomal Expression And Regulation, 
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promoter element which is bound by the transcription factor EB (TFEB).  Lysosomal disruption 
results in the coordinated upregulation of genes, mainly encoding lysosomal proteins, in this 
network through TFEB activation (18). Since the original study, the CLEAR network has been 
shown to drive expression of proteins in additional degradation pathways (73).  This is the first 
evidence of a gene network that can alter lysosomal levels suggesting that cells can monitor and 
respond to changes in the endocytic pathway at a transcriptional level.   
1.2.2 Synthesis and trafficking of lysosomal proteins 
Lysosomal composition includes both hydrolytic enzymes as well as a system of 
transporters that play several important roles as discussed above. These include: (i) establishing 
and controlling acidic pH in the lysosomes, (ii) cleavage of specific substrates, (iii) absorption of 
digestive substrates, (iv) the release of Ca2+ from the lysosomal lumen that drives the fusion of 
lysosomes with late endosomes, and (v) transport of metals bound to endocytosed proteins across 
the lysosomal membrane into the cytoplasm (30-32).  Hydrolytic enzymes are targeted to the 
lysosomal lumen, while transporters are delivered to the membrane through vesicle fusion.  
Targeting to the lysosome can occur in mannose 6-phosphate dependent and independent 
manners through the biosynthetic and endocytic pathways.  The following section will describe 
the trafficking and sorting of lysosomal proteins through these pathways. 
All lysosomal proteins are co-translationally transported into the endoplasmic reticulum 
(ER) (74, 75).  Hydrolytic enzymes are transported into the ER lumen while lysosomal 
membrane proteins (LMPs) are inserted into the ER membrane.  I will first discuss the sorting of 
hydrolytic enzymes, which are delivered directly to lysosomes from the trans-Golgi network 
(TGN), modeled in Figure 1.1.  In the ER the hydrolases are modified, specifically through 
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glycosylation on asparagine residues within the consensus motif Asn-X-Ser/Thr with high 
mannose oligosaccharides (76).  These glycans are then processed by glucosidases and 
mannosidases before being transported to the Golgi complex (Fig 1.1.A) (77).  Further 
processing may occur depending on the nature of the lysosomal protein, for example, specific 
cysteine residues are converted into Cα-formylglycine residues in lysosomal sulfatases, a 
modification essential for proper sulfatase activity (78).  The hydrolases are then transported to 
the Golgi complex via vesicular transport. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
 
Figure 1.1 Model of biosynthetic trafficking of lysosomal hydrolytic enzymes 
Schematic model of hydrolytic enzyme trafficking from the ER to the TGN to lysosomes.  A. Hydrolytic enzymes 
are translated into the lumen of the ER, where they are glycosylated.  This moiety is processed removing glucose 
residues and a mannose residue, before exiting the ER.  B.  In the early Golgi, a phosphodiester intermediate is 
formed mainly on the first mannose of the α-1,6 branch of the mannose chain.  This is then hydrolyzed by the 
“uncovering enzyme” revealing the phosphate group.  This structure is recognizing in the TGN by mannose-6-
phosphate receptors (M6PRs)  C.  M6PRs associate with adaptor proteins such as AP-1, which mediates interaction 
with clathrin to form clathrin-coated vesicles.  D.  Clathrin coated vesicles from the TGN are transported to early 
endosomes.  Here the M6PR dissociates with its cargo upon exposure to the acidic lumen of these vesicles.  The 
M6PR is recycled back to the TGN or is transported to the plasma membrane.  The early endosome matures/fuses 
with the late endosomes, which fuses or transfers cargo to the lysosome.  In the lysosome the inactive hydrolases are 
activated.  Model adapted from figures in Pohl et al., 2009 and Braulke and Bonafacino, 2009. 
 
 12 
Upon reaching the Golgi, the high mannose chain is either mono- or diphosphorylated by 
GlcNAc-1-phosphotransferase, resulting in a phosphodiester intermediate (79, 80).  The primary 
phosphorylation event occurs on the first mannose of the α-1,6 branch of the mannose chain, 
resulting in the name mannose-6-phosphate.  The second phosphorylation site can occur on the 
first mannose of the α-1,3 branch (81, 82).  Following these phosphorylation events, an enzyme 
called the “uncovering enzyme”, or UCE, cleaves the GlcNAc revealing the mannose-6 
phosphate (Fig 1.1 B) (83).  The mannose-6 phosphate residues are recognized and bound by 
mannose-6-phosphate receptors, CD-MPR and CI-MPR, in the trans-Golgi compartment, 
segregating them from secretory proteins (84).  The receptor-cargo complex is transported in 
clathrin coated vesicles, mediated by the association with AP-1 and GGA (Golgi-localized, γ-
ear-containing, Arf-binding family of proteins) adaptors (Fig 1.1.C) (85), from the Golgi to pre-
lysosomal compartments such as early and late endosomes.  Upon fusion with the pre-lysosomal 
compartments the mannose 6-phosphate receptors dissociate from their cargo due to the acidic 
endosomal pH and are recycled to the Golgi complex or plasma membrane (86, 87).  Delivery of 
acid hydrolases is completed when the late endosome fuses or transfers material to the lysosome, 
as seen in Figure 1.1.D.  Lysosomal hydrolases arrive in an inactive “zymogen” form, but are 
then activated by homo- or heterocleavage by mature enzymes in the lysosome (88).  
Interestingly, it has been shown that increasing endocytic vesicle pH, through the treatment of 
modulators such as Bafilomycin A1, ammonium chloride, and chloroquine, results in acid 
hydrolases entering the secretory pathway (60, 61, 89), demonstrating that the acidic identity of 
these organelles is crucial for proper delivery of lysosomal components. 
Although the mannose 6-phosphate receptor pathway is the most prevalent lysosomal 
sorting method, several mannose-6 phosphate receptor independent pathways have been 
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identified.  For example, the receptor sortilin has been implicated in the sorting of prosaposin 
and acid sphingomyelinase (90, 91) and the lysosomal membrane protein LIMP-2 is suggested to 
mediate sorting of β-glucocerebrosidase (92).  In addition, some secreted lysosomal proteins 
have been shown to be re-internalized through endocytosis, resulting in their delivery to the 
lysosomes.  The final evidence for mannose-6-phosphate receptor independent delivery of 
lysosomal proteins stems from the observation that in cell systems lacking mannose-6-phosphate 
receptors, several tissues retain normal levels of properly delivered hydrolases (84). 
Unlike hydrolytic enzymes, LMPs do not follow a mannose-6-phosphate receptor sorting 
pathway.  These proteins contain targeting signals in their cytoplasmic tail domains and are 
sorted either directly from the TGN or through the plasma membrane (87).  These signals are 
often linear tyrosine or di-leucine based motifs, however in the past several years other signals 
such as ubiquitin have also been shown to direct the delivery of LMPs  (93).  The sorting of 
LMPs through the plasma membrane is fairly well understood, while direct sorting through the 
TGN is not as well established.  In indirect delivery, LMPs follow the secretory pathway to the 
plasma membrane where they are then endocytosed and are delivered through the endocytic 
pathway to the lysosome.  The direct pathway suggests that LMPs follow a similar route as 
hydrolytic enzymes, without the need of mannose chains/mannose-6-phosphate receptor.  
However, the dynamics of this pathway are not well defined due to that fact that although LMPs 
have been shown to interact with the AP-1 and clathrin, which direct the formation and sorting of 
clathrin coated vesicles to early and late endosomes (94, 95), they are also properly sorted in 
systems lacking AP-1 and clathrin (96, 97).  This suggests that additional sorting components 
may be able to compensate for the loss of these proteins, resulting in the proper delivery.  
Interestingly, it was recently shown that LMPs interact with ubiquitinated GGA3, an adaptor 
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protein which is thought to also interact with mannose-6-phosphate receptors, resulting in 
lysosomal delivery (98). This suggests that ubiquitin is a common sorting signal for LMPs.   
1.2.3 Lysosomal storage disorders 
Lysosomal storage disorders (LSDs) are a class of about 50 diseases caused by the 
malfunction, loss, or improper delivery of lysosomal or endocytic components, critical for proper 
lysosomal function.  The majority of these disorders are autosomal recessive genetic diseases 
that arise from single gene mutations (2, 99-101).  These disorders are often classified by the 
resulting substrate accumulation, although the basis and severity of this accumulation may differ 
(i.e. Mucopolysaccharidoses, Sphingolipidoses, and Glycoproteinoses).  The first link between a 
disease and the loss of a lysosomal component was in 1963, identifying the loss of α-glucosidase 
as the cause of Pompe disease (102). Since then the majority of identified LSDs have been linked 
to defects in hydrolytic enzymes, resulting in the buildup of specific substrates.  However several 
LSDs arise from the loss of LMPs; these disorders are not as easily treatable and do not result in 
the accumulation of specific substrates.  
LSDs are characteristically neurodegenerative disorders (although there are exceptions 
such as type I Gaucher’s disease and Pompe disease) resulting in motor defects, abbreviated life 
span, impaired vision, and peripheral defects.  At a cellular level, LSDs often result in the 
accumulation of dense cellular inclusions filled with undigested substrates, although the 
composition of these inclusions differs between diseases (103-105). The buildup of undigested 
substrates appears to cause similar secondary defects shared between several disorders.  These 
include oxidative stress, improper Ca2+ handling, perturbed metabolic function, and impaired 
autophagy (14, 15, 106-109).  The appearance of these secondary defects has become a problem 
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in studying the molecular mechanisms driving LSDs as they convolute the model system.  For 
example, most LSD studies are performed in patient cells, which have already built up cellular 
inclusions and developed these secondary defects (110-114).  Understanding these downstream 
effects is important for treatment, however these chronic models make it difficult to study the 
primary effects of dysfunction, especially in diseases that are not enzymatically based. 
Deficiencies in lysosomal components often arise from genetic mutations resulting in 
improper delivery to the endocytic pathway, improper folding, or inactivation of lysosomal 
proteins.  These defects can be directly related to the lysosomal components or affect 
components required for proper delivery or function of the enzyme.  For example, mucolipidosis 
II & III result from mutations in the gene GNPTA, which results in the loss of UDP-N-
acetylglucosamine-1-phosphotransferase (or GlcNAc-1-phosphotransferase) (115).  As discussed 
in section 1.2.2., this enzyme is required for the production of the mannose-6-phosphate tag in 
the Golgi.  Therefore, mannose-6-phosphate dependent trafficking is ablated, resulting in higher 
levels of secreted hydrolases and reduced lysosomal levels (116).  Additional, non-lysosomal 
mutations such as the loss of Cα-formylglycine generating enzyme (FGE), which is required to 
convert cysteine residues in sulfatases (as mentioned in section 1.2.2.) and the loss of 
sphingolipid activator proteins (called saponins), result in the disorders Multiple Sulfatase 
Deficiency and GM2 gangliosidosis respectively (99, 117, 118).   
In addition to LSDs caused by the improper processing or trafficking of lysosomal 
enzymes, there are several disorders characterized by the loss of LMPs.  Such is the case in 
Mucolipidosis Type IV (MLIV), which will be discussed more broadly in section 1.3.  Other 
disorders classified by loss of LMPs include variants of neuronal ceroid lipofuscinosis (NCLs) 
caused by the loss of several uncharacterized transmembrane proteins: CLN3, CLN6, CLN7, and 
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CLN8 (119-122).  The discovery of such disorders reveals that there are disorders that affect 
proteins which are responsible for regulating and maintaining the lysosomal ionic environment 
and that there are several classes of LMPs which are uncharacterized, displaying the complexity 
and thus unknown dynamics of the lysosome.  Such discoveries display new opportunities in 
understanding the workings of the lysosome as well as the treatment of such disorders.     
1 in 7000-8000 births is affected by LSDs, even though individual LSDs are far rarer 
(123-126).  The prevalence of LSDs and the fact that they arise from lysosomal malfunction 
suggests this wide class of disorders may share similar molecular consequences and therefore 
may need both specific and non-specific treatments to address disease pathology.  LSD 
treatments have progressed dramatically in the past several years including specific treatments 
such as enzyme replacement therapy, substrate reduction, pharmacological chaperones, and gene 
therapy.  The most effective and broadly used specific treatment in both human and mouse 
models is enzyme replacement therapy.  This approach is limited by the ability of the enzyme to 
cross the blood brain barrier (127, 128).  In the past several years this problem has been 
addressed by such techniques as fusing the target enzyme to a protein that can cross the barrier, 
such as apolipoprotein B, and is then endocytosed into the cells (129, 130).   Although this 
treatment does not completely correct disease pathology, it seems the development of such 
treatments can at least promise alleviation of some disease symptoms. Currently, enzyme 
replacement therapy is available for Gaucher, Fabry, mucopolysaccharidosis I & IV (MPS-I, 
MPS-VI), and Pompe disease (126).   
Some “non-specific” treatments are being employed to address common pathologies in 
LSDs, such as inflammation.  Such methods include the use of anti-inflammatory drugs and bone 
marrow transplant which have been shown effective in the treatment of specific disorders.  Bone 
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marrow transplant is only beneficial when the disease is caused by enzyme deficiencies, with the 
donor macrophages and glia cells partially correcting enzyme levels in nearby neurons.  Despite 
the neurological benefits of this approach, it is less effective in treating the motor and peripheral 
abnormalities of disease and must be administered before the onset of symptoms in order to be 
effective (131-133).  Both bone marrow transplant and anti-inflammatory drug treatments have 
been shown effective in helping limit the inflammatory effects of LSDs, in mouse and human 
disease models (134, 135).     
The most promising field in LSD treatment seems to be combining specific treatments 
(such as gene therapy and substrate reduction) with some non-specific treatments that address 
secondary/peripheral effects (such as bone marrow transplant or anti-inflammatory drugs) (126).  
Combined treatments help address multiple aspects of the disease; however, these treatments are 
targeted to diseases caused by enzyme deficiencies.  A major question is how to treat LSDs that 
are not enzymatically based since enzyme replacement is not an option in these cases.  In order 
to treat such disorders we must first understand the underlying causes of cell death in these 
diseases.  Although we may treat the symptoms of these disorders, it is clear that addressing the 
cause of neurodegeneration and peripheral deterioration holds the key to treatment.  To better 
understand how the loss or alteration of lysosomal components, such as LMPs, effects cell 
function we must study the direct effects of losing such components.  These effects may hold the 
key to understanding the function of such proteins in the lysosome and how their loss contributes 
to disease pathology and cellular death.  In the next section, I will discuss how the altered 
localization of a lysosomal component can indeed directly contribute to cell death.    
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1.2.4 Cathepsin-induced Apoptosis 
Cathepsin proteins are major proteolytic enzymes localized to the lysosome.  As 
previously discussed, specific Cathepsin proteins maintain activity in higher pH environments 
outside the lysosome.  Interestingly, several Cathepsins have recently been linked to apoptosis 
suggesting that leakage of these lysosomal hydrolases may cleave pro-apoptotic factors driving 
cell death (58, 136-140).  The role of Cathepsin B in apoptosis is investigated in this study 
therefore a brief background describing the role of Cathepsins in cell death is discussed below.  
This background section will focus mainly on Cathepsin B, although there are some similarities 
shared between this protease and other lysosomal proteases. 
The Cathepsin family of papain-like proteins can be broken up into exopeptidases and 
endopeptidases and is further classified by the amino acids which coordinate their catalytically 
active sites.  Cathepsin B is a cysteine protease which exhibits both endopeptidase and 
exopeptidase activity.  It is unique among lysosomal cathepsins in this regard where cysteine 
Cathepsins D, H, L, and S and the aspartic Cathepsin D are strictly endopeptidases (141, 142).   
Cathepsins are synthesized and trafficked as described in section 1.2.2.  Upon entering 
the endocytic pathway, these proteases are in an inactive proenzyme form, called a zymogen, 
which contains a proregion blocking the catalytic domain.  This domain must be cleaved in order 
to activate the enzyme.  Cathepsin B contains an ~62 amino acid propeptide (143) which is 
cleaved by mature forms of Cathepsin B (144). Upon cleavage, the mature monomer (~20-30kD) 
is composed of two domains responsible for forming the catalytic pocket of the enzyme.  
Similar to other Cathepsin proteases, mature Cathepsin B is defined by a left domain 
consisting of 3 α-helixes, and a right β-barrel domain.  However, Cathepin B is unique in that it 
contains an insertion, called the occluding loop, which is thought to confer exopeptidase activity 
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to the enzyme, coordinated by an ion pair formed from a histidine and aspartate interaction (145, 
146).  The endopeptidase catalytic cleft of Cathepsin B is located between the left and right 
domains, coordinated by a cysteine residue in the left domain and a histidine and asparagine in 
the right domain (147, 148).  This triad is conserved between cathepsins demonstrating its 
importance to proteolytic activity (149).  The thiol group of the cysteine and the imidazolium 
ring of the histidine form an ion pair at acidic pH ranges.  In the presence of a substrate, a 
neutrophile attack of the carbonyl carbon by the ionized thiol results in the formation of a 
covalent intermediate between the protease and its substrate, followed by proteolytic cleavage of 
the substrate.  Cathepsin B’s endopeptidase activity favors cleavage of amino acids upstream of 
bulky hydrophobic sidechains as well as arginine residues while the exopeptidase activity 
cleaves two C-terminal amino acids demonstrating preference for large aromatic side chains 
(150-152).   
Cathepsin localization and the suitable pH conditions of the lysosome suggested that 
these proteases only operated in this organelle.  However, in the past several years, it has been 
shown that release of specific cathepsins from the lysosome into the cytosol can promote 
apoptosis.  It has been demonstrated that Cathepsin D plays a role in apoptosis under several 
conditions; however both Cathepsin B and Cathepsin L were also recently shown to play a role 
in apoptosis (57-59, 136, 137, 153-155).  Cathepsin-mediated apoptosis in some cases appears to 
be caspase-independent (156, 157), however the majority of Cathepsin-mediated apoptosis is 
mediated by several pro-apoptotic cellular components including Bid, Bax, and caspases, such as 
caspase-8 and 3.  The release of Cathepsins into the cytosol promotes cleavage of these 
substrates (i.e. Bid and caspases) resulting in mitochondrial fragmentation and subsequent 
apoptosis (58, 59, 138, 158, 159).  However Bax and caspase-8 have both been shown to mediate 
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the release of Cathepsins from lysosomes.  Therefore where Cathepsins lie in the apoptotic 
pathway is still unclear and may vary depending on the cell type and the apoptotic stimulus (59, 
136).  The diversity of these pathways shows that this process is complex, thus teasing apart 
these cellular systems could provide insight into how cells respond to their environment. 
 
1.3 TRPML1 
 
TRPML1 (or mucolipin-1) is the first member of the TRP family of ion channels that was 
found to function in deeper portions of the endocytic pathway. Mutations in the gene coding for 
TRPML1 (MCOLN1) cause the lysosomal storage disease mucolipidosis type IV (MLIV). 
TRPML1 localization in the lysosomes and the similarity of the MLIV phenotype to LSDs 
whose origin has been directly linked to lysosomal dysfunction, suggest that TRPML1 activity 
drives some vitally important processes within the endocytic machinery. The specific aspect(s) 
of TRPML1 activity that make it indispensable for proper endocytic function are currently 
unclear. Possible functions of TRPML1 are membrane fusion within the lower portion of the 
endocytic pathway possibly mediated by Ca2+ release through TRPML1 itself or regulation of 
lysosomal ion homeostasis (pH or Fe content) (160-162).  In addition to delineating the 
mechanisms of MLIV pathogenesis, identifying the role of TRPML1 in the endocytic pathway 
will lead to important developments in our understanding of this system and, due to the 
neurodegenerative nature of MLIV, how loss of this channel affects specific cell types. The 
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following section will focus on developments in identifying the TRPML1 function as well as 
established TRPML1 characterization. 
1.3.1 TRPML1 characterization 
TRPML1 was cloned by three labs in 2000 as a result of the search for the genetic 
determinants of MLIV (2, 11, 163). The gene MCOLN1 (NG_015806, NM_020533) coding for 
TRPML1 is located on human chromosome 19 (19p13.2–13.3) spanning base pair positions 
7,587,511–7,598,863. MCOLN1 is fairly conserved within Vertebrata; no splice variants have 
been reported in the human gene, although variants have been reported in mice (164). In 
Drosophila, the entire TRPML family is represented by a single trpml gene (Dmel_CG8743, 
NM_140888, chromosome 3L, location: 76C2–76C2, base pairs 19,706,960–19,711,450). In C. 
elegans, TRPML is represented by the cup-5 gene (R13A5.1, NM_001027550, NM_001027548, 
NM_066263, NM_001027551, chromosome III, location: 378–564, base pairs: 7584129–
7591495).    
 TRPML1 is a member of the TRPML (mucolipin) subfamily of the TRP family of ion 
channels.  All TRPML channels function in the endocytic pathway, which sets them apart from 
other TRP channels. Like all TRP channels, TRPML1 is presumed to have 6 transmembrane 
domains; its putative pore lies between the 5th and 6th domains. The structure-functional 
determinants of TRPML1 function have not been explored in detail; it does not seem to possess 
the full TRP box signature domain or ankyrin repeats present in some other TRP channels, which 
may mediate the function and anchoring of TRP channels respectively. Both C- and N-termini of 
TRPML1 contain putative lysosomal localization signatures, although only the N-terminal di-
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leucine motif has been verified (6).  The significance of a large loop connecting the 1st and 2nd 
domains (1) and PKA-dependent phosphorylation sites (165) have not been explored in detail 
although some data suggest proteolytic cleavage of the loop and phosphorylation of the PKA-
dependent domains as modulatory inputs.  
1.3.2 Proposed Models of TRPML1 Function 
There are two models of proposed TRPML1 function: a trafficking model and a 
metabolic model.  The trafficking model suggests TRPML1 regulates delivery and fusion/fission 
of vesicles along the endocytic pathway while the metabolic model suggests that TRPML1 
regulates the ionic environment of the lysosome driving proper enzymatic function.  The 
trafficking model is supported by the initial set of conclusions regarding TRPML1 function, 
inferred from the conductance characteristics of the currents that were associated with TRPML1 
expression and measurement of membrane traffic and lysosomal enzymatic activity in fibroblasts 
obtained from MLIV patients (primarily the WG0909 clone). A combination of the initial reports 
on Ca2+ permeability through recombinant TRPML1 expressed in HEK293 cells (3, 160) or 
reconstituted into lipid bilayers (10, 166) and the delays in the lipid traffic reported in MLIV 
fibroblasts (167, 168) and in the C elegans MLIV model (169, 170) gave rise to the idea that 
TRPML1 is a lysosomal Ca2+ release channel. According to this trafficking model, Ca2+ release 
through TRPML1 drives the Ca2+ dependent step of SNARE-mediated lysosomal-endosomal 
fusion.  Without the TRPML1-mediated Ca2+ release, substrate delivery is impaired, limiting the 
exposure of endocytosed material to active digestive enzymes, resulting in the buildup of 
undigested material within the endocytic pathway. A direct consequence of this model would be 
a general deficit in the membrane traffic within the endocytic pathway. Although such deficits 
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have been shown in MLIV fibroblasts and in the C elegans model (167-170), it is unclear 
whether they are a direct consequence of TRPML1 loss or a secondary effect of undigested 
material buildup.  
The second model is built on the fact that membrane traffic delays similar to those 
reported in MLIV were also demonstrated in cells affected by LSDs of clearly “metabolic” origin 
(e.g. sphingolipid storage diseases) (171). This model suggests that TRPML1 regulates some 
aspects of lysosomal ion homeostasis and that dysregulation of this homeostasis in the absence of 
TRPML1 leads to chronic or acute loss of the lysosomal digestive function. This scenario is 
similar to the loss of lysosomal digestive function upon downregulation of the lysosomal Cl– 
channel ClC-7 (70).  Both models present several unresolved questions concerning the causal 
relationships between TRPML1 loss and the resulting phenotypes that were used to formulate the 
models. Specifically, the core features of the trafficking model do not distinguish if the delays in 
lipid traffic are a direct result of TRPML1 loss or whether they are caused by the buildup of 
undigested material “clogging” the membrane traffic machinery. The metabolic model does not 
answer whether the ionic dysregulation observed in TRPML1 deficient cells is a direct effect of 
TRPML1 loss or whether it reflects a cellular response to TRPML1 loss, perhaps at a 
transcriptional level.  In order to further delve into these models and study TRPML1 function, a 
new set of techniques has been recently established.  The following section will discuss these 
approaches and their implications in understanding TRPML1 function and its link to disease.  
Table 1.1 summarizes the results used to formulate both models of TRPML1 function.  
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Table 1.1  Models of TRPML1 loss and the resulting phenotypes 
MLIV patients 
Progressive neurodegeneration with early onset, mental 
retardation, corneal opacity, retinal degeneration, vacuolization 
of parietal cells, constitutive achlorhydria, elevated gastrin 
levels (172-182) 
Mouse TRPML1 knockout Neurological defects including gait deficits and hind-limb paralysis; elevated plasma gastrin, vacuolization in parietal 
cells, and retinal degeneration (13) 
Drosophila trpml mutants Neurodegeneration with accumulation of apoptotic cells in the brain, impaired synaptic transmission, impaired autophagy and 
mitochondrial function; lysosomal overacidification (15) 
C. Elegans CUP-5 mutants Impaired endocytosis and lysosomal biogenesis (4, 169, 183) 
Human MLIV fibroblasts Impaired membrane traffic (167, 168) and exocytosis (184) 
Human MLIV fibroblasts & 
Drosophila trpml mutants 
Impaired autophagy (14, 15, 165, 185) and mitochondrial 
function (14, 15) 
 
MLIV fibroblasts, HeLa 
acute KD, Drosophila trpml 
mutants 
Lysosomal overacidification (15, 162, 186) 
HeLa acute KD, Drosophila 
trpml mutants 
Normal membrane fusion in the endocytic pathway (15, 162) 
Recombinant TRPML1 
expression 
Permeable to Ca2+ (3, 8, 10, 160, 166, 187), H+ (186), and Fe2+ 
(188).  Potentiated by H+ (8) and inhibited by H+ (166, 189) 
 
1.3.3 New techniques of studying TRPML1 function 
 The following techniques are being used to study TRPML1 function in a system which 
lacks secondary defects caused by substrate accumulation, so that we may better understand the 
role of this channel in the endocytic pathway.  The first approach aims to identify the immediate 
consequences of TRPML1 loss on membrane traffic in the endocytic pathway.  Two groups 
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downregulated TRPML1 expression using RNAi; the first studied the effects of acute TRPML1 
knockdown using siRNA (162) while the second used a constitutively active shRNA expression 
system resulting in longer knockdown periods (190). Both studies documented delayed 
translocation of fluorescent lipids from lysosomes to the Golgi indicating that TRPML1 either 
modulates lipid modifications preceding lipid translocation from lysosomes to Golgi or it 
regulates membrane traffic events in this step. Analysis of pre-lysosomal trafficking defects in 
these studies produced varied results. Using stable line shRNA knockdown of TRPML1, a delay 
in lysosomal delivery of lipids from the lysosome to the Golgi was shown in TRPML1-deficient 
murine macrophages (190), while no delay was observed in acute 48 hour TRPML1 knockdown 
in HeLa cells (162). Further studies will elucidate whether the loss of TRPML1 results in 
trafficking defects along later portions of the endocytic pathway. It is interesting to note that 
delayed lipid delivery was seen in the stable TRPML1 knockdown line similar to delays seen in 
MLIV fibroblast cells (167, 168) suggesting that chronic loss of this channel could lead to 
secondary effects that result in trafficking delays. A detailed investigation of lipid hydrolysis and 
modification caused by acute TRPML1 loss will be necessary to clarify its role in lipid handling 
within the endocytic pathway. The acute model of TRPML1 knockdown provides an exciting 
new tool for studying the direct cellular responses to TRPML1 loss.  
 The next novel approach to studying TRPML1 function has been through structure-
function analysis based on structural comparison with its relative TRPML3 and other voltage-
gated ion channels.  These studies have revealed a region resembling the linker sequence in the 
voltage-gated channels that translates the movement of the voltage-sensing domain to the 
opening and closing of the pore. Mutating this region in TRPML1 resulted in spontaneously 
active currents that, similar to previously published data, carried Ca2+ (3, 8, 10, 160, 166, 187), 
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but contrary to some of the previously published data, was activated by low pH (8, 166, 189). 
Single channel recordings of TRPML1 activity confirmed its regulation by pH (191). These data 
provide support for the role of TRPML1 in Ca2+ dependent maturation and fusion of endocytic 
compartments.  However, one major caveat of the previously described studies was the inability 
to measure TRPML1 activity in the lysosomal environment.  An exciting new technique was 
recently developed to enlarge lysosomes, making them accessible to patch clamp analysis.  
These studies demonstrated Fe2+ permeability through TRPML1 (188). It is an interesting 
possibility indeed that TRPML1 is a Fe2+ shunt that allows efflux from lysosomes that mitigates 
the effects of Fe2+ buildup, which otherwise leads to, among other things, accumulation of 
lipofuscin (buildup of undigested lipid material) in the lysosomes. A detailed chemical and 
structural analysis of storage bodies in TRPML1 deficient cells and comparison of their content 
with classic Fe2+ overload and lipofuscin buildup models will help test this interesting model.  
 The final line of research aimed at clarifying the role of TRPML1 in the endocytic 
pathway is focused on identifying the molecular context of TRPML1 activity, analyzing its 
activity and protein interactions in the lysosomal environment. As the first step towards this goal, 
the protein ALG-2 (EF-hand-containing protein apoptosis-linked gene 2 protein) suggested to be 
a sensor for mediating Ca2+ dependent vesicle fusion (192), was found to bind to TRPML1 in a 
Ca2+ dependent manner (55). That ALG-2 is a putative Ca2+ binding protein suggests that Ca2+ 
regulates TRPML1, or that the effects of Ca2+ currents through TRPML1 are actuated by ALG-2. 
Further analysis of the functional consequences of TRPML1 interaction with ALG-2 and with 
other proteins will delineate how the environment of the lysosome modulates TRPML1 activity. 
 27 
1.3.4 MLIV 
MLIV is caused by mutations in the gene MCOLN1, coding for TRPML1.  Onset of 
MLIV begins within a year of birth and has a severe neurodegenerative profile, presumably due 
to the loss of brain tissue. Other pathological manifestations of MLIV include corneal opacity, 
retinal degeneration and constitutive achlorhydria, and a decrease in gastric acid secretion (172-
182). MLIV cellular pathology is characterized by the buildup of storage bodies and vacuoles 
throughout patient tissues (215). This disease is most prevalent in the Ashkenazi Jewish 
population with a reported carrier frequency of 1:100 (216), with the majority of mutations 
obliterating TRPML1; some mutations result in improper localization or channel function (1, 
166, 217, 218). The mechanism of cell death in MLIV is poorly understood, despite the obvious 
benefits promised by delineating such pathways. Some recent data suggest autophagic 
dysfunction and buildup of dysfunctional mitochondria as a possible pathway of cell death in 
LSDs, specifically in MLIV (5, 14). Similar conclusions were obtained using the Drosophila 
model of MLIV obtained by knockout of the single TRPML coding gene in Drosophila (15). 
Understanding the underlying cause of TRPML1 loss as well as the downstream effects that may 
result in cell deterioration are critical for treatment of this disorder. 
Like all LSDs, MLIV is marked by the buildup of undigested substrates in cellular 
inclusions.  These inclusions have been shown to contain sphingolipids, mucopolysaccharides, 
and phospholipids, suggesting that loss of TRPML1 inevitably results in the dysfunction of 
several lysosomal hydrolases (167, 174). Differences between inclusion materials has been 
shown between cell types, possibly caused by cell-specific reactions to TRPML1 loss (219), 
controlled at the proteomic or transcriptional levels  (220). One physiological example of such a 
reaction may be in the pronounced buildup of vacuoles in parietal cells, the stomach epithelial 
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cells that produce gastric acid, which underlie constitutive achlorhydria, low production of 
gastric acid, documented in MLIV patients (181). Parietal involvement and achlorhydria may 
directly point to TRPML1 function, or may result from a response of specific subsets of cells to 
the problems in the endocytic pathway caused by the TRPML1 loss.  Delineating cell-specific 
responses to TRPML1 loss may reveal both the function of this channel as well as how cells 
differentially respond to endocytic insults.    
Multiple roles of TRPML1 have been proposed, as discussed in section 1.3.  Disparities 
between studies in patient fibroblast cells suggests that the key to delineating TRPML1 function 
and the cause of MLIV pathogenesis may lie in identifying cellular responses to acute TRPML1 
loss.  Furthermore, understanding the regulation of TRPML1 channel activity and its role in ion 
transport may reveal the endocytic role of this protein.  The following work uses multiple 
approaches to answer the following questions: i) What is the cellular response to acute TRPML1 
loss at the proteomic/lysosomal level, ii) Does TRPML1 loss induce specific transcriptional 
changes, and iii) Can we clarify the role of TRPML1 in ion transport using spontaneously active 
mutants and TRPML3 as a comparative model?  By answering these questions, I hope to provide 
a better understanding of TRPML1 cellular function, separate primary effects of TRPML1 loss 
from secondary defects, and link cellular responses to TRPML1 loss to cell death. 
 
1.3.5  Transition metal toxicity and TRPML1  
Transition metals are well-known environmental hazards that cause systemic 
degenerative processes (193, 194).  Excessive exposure to metals can occur from occupational 
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hazards, accidents, high dietary uptake, and genetic disorders which inhibit metal metabolism 
(193).  Fe2+ has been shown to overload the heart and liver, causing heart failure and even death 
(194). Cu2+ toxicity also leads to liver and brain damage resulting in coma, hepatic necrosis, 
vascular collapse, and death (193). The accumulation of Cu2+ in the genetic disorder Wilson’s 
disease results in neuronal and cardiac defects such as cerebellar dysfunction, congestive heart 
failure, and cardiac arrhythmia (195).  The wide spectrum of clinical representation of transition 
metal toxicity suggests that cell handling of these metals is crucial for maintaining proper 
function.   
In tissues that absorb transition metals such as the brush border epithelial cells of the 
intestine or lung, liver and kidney, these metals enter the cytoplasm directly via plasma 
membrane transporters such as Slc31a1 (also called Ctr1) (196, 197) and Slc11a2 (also called 
DMT1, NRAMP2) (65, 66). Metals are removed from cells by metal-chaperones or through 
excretion pumps such as ATP7a or Slc40a1 (Fpn, MTP1) (197) (66).  The effects of transition 
metals in the cytoplasm is the most widely studied model of metal toxicity and such studies 
provided the rationale for the use of metal chelators to combat acute transition metal toxicity. 
In non-absorbing tissues, cells do not require a high metal intake, therefore they lack high 
levels of plasma membrane transporters and metals enter through the endocytosis of free metals 
and metal-bound proteins (65, 66, 197). In addition to Fe2+ and Cu2+ other transition metals such 
as Fe3+, Zn2+ and Co2+ can enter the cell through this pathway.  These metals travel through the 
endocytic pathway until they are excreted into the cytoplasm by transporters, such as Slc11a2 
(DMT1), expressed at low levels in lysosomes (198). Under normal conditions, the majority of 
transition metals are bound to plasma proteins such as albumin, transferrin and ceruloplasmin 
(65, 66, 197). Degradation of these proteins in the endocytic pathway releases the metals into the 
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lysosomal lumen. The active chemical environment of the lysosomal lumen promotes Fenton-
like chemical reactions (a reaction between a catalyst such as iron and hydrogen peroxide 
producing a hydroxide radical) resulting in generation of free radicals, which are damaging to the 
lysosomal membrane and result in the production of the inert chemical compound called 
lipofuscin (199, 200).  
The acute exposure to high concentrations of transition metals has been linked to 
lysosomal storage phenotypes (194, 201, 202) and to lysosomal permeabilization (203, 204). 
Long-term exposure to transition metals, e.g. in postmitotic cells, has been linked to buildup of 
lipofuscin, which inhibits lysosomal function and autophagy (205, 206). Autophagy deficits have 
been shown in several models of LSDs (13-15, 112, 165, 207-210) and in transition metal 
overload (211, 212). According to the lysosomal-mitochondria axis models of aging and cell 
death in LSDs, the suppression of autophagy results in buildup of dysfunctional organelles, 
specifically mitochondria (205, 206). Our lab has previously suggested that the loss of 
mitochondrial Ca2+ buffering capacity and of the Ca2+-driven ATP production positive feedback 
loop makes cells vulnerable to the pro-apoptotic effects of stimulation with Ca2+ mobilizing 
agonists (neurotransmitters, hormones, growth factors) as seen in Figure 1.2 (14, 209). 
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Figure 1.2. Mitochondrial fragmentation in storage diseases due to defects in autophagy may promote 
proapoptotic pathways. 
In normal cells (left), mitochondria act as a buffering system for Ca2+.  The buildup of effete mitochondria (right) in 
storage diseases, due to impaired autophagy, may result in an increase in cytoplasmic Ca2+.  These increases may 
drive proapoptotic pathways, resulting in increased cellular death in LSDs.  Model from Kiselyov et al., 2011 (213). 
 
 
The detrimental effects of transition metals in the lysosomes, combined with the cellular 
requirements for transition metals necessitate extraction of the metals from the lysosomal lumen 
into the cytoplasm, where their effects can be mitigated by chelating proteins or by extrusion out 
of the cell (66, 197). Existence of such mechanisms has been shown before. Specifically, 
Slc11a1 (NRAMP1) and Slc11a2 (NRAMP2, DMT1) are ion transporters responsible for 
divalent cation uptake by cells (65, 66). The intracellular localization of Slc11a2 and its apparent 
role in export of divalent cations from the lumen of lysosomes led to the suggestion that this 
channel is, or is part of, the endocytic divalent cation absorption pathway. Recently published 
data suggests that Slc11a2 is not the only mechanism for transition metal absorption in the 
endocytic pathway and may implicate TRPML1 as a possible transition metal channel (188, 
214).   
TRPML1 has recently been proposed to function as a release channel for Fe2+ and Zn2+, 
exporting these transition metals from the lysosomal lumen into the cytoplasm to prevent Fenton 
reactions and the buildup of lipofuscin catalyzed by Fe2+.  Evidence in support of this function 
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was shown in MLIV patient fibroblasts which contain higher lysosomal levels of Fe2+ than 
matched controls, further suggesting that TRPML1 may function as an Fe2+ release channel 
(188).  Furthermore, Zn2+ accumulation was also demonstrated in MLIV fibroblasts and using a 
combination of electrophysiology and chemical analysis, Zn2+ permeability through TRPML1 
was observed (214).  The limitations of recording physiological recordings from TRPML1 have 
hindered the complete understanding and dynamics of TRPML1 as a transition metal release 
channel, however future studies may elucidate its role.  These studies provide an interesting 
possibility for existence of a novel metal export pathway from the lysosomes and suggest that 
transition metals may play a critical role in disease phenotype in MLIV and perhaps other LSDs. 
1.4 GOALS OF THIS DISSERTATION 
In the following chapters I will study TRPML function using models of acute endocytic 
disruption.  In the first two chapters I will use acute siRNA-mediated knockdown of TRPML1 
and measure the cellular effects of TRPML1 loss.  I hope to identify direct cellular responses 
triggered by the loss of this protein, specifically in the context of cell death and differential gene 
expression.  In the last chapter, I will study the closely related ion channel TRPML3 and its 
interaction with transition metals.  Furthermore, I will test whether transition metals inhibit the 
endocytic pathway and if their interaction with TRPML3 mediates this dysfunction. 
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2.0  CATHEPSIN B MEDIATED APOPTOSIS IN TRPML1 DEFICIENT CELLS 
2.1 ABSTRACT 
Mucolipidosis type IV (MLIV) is a lysosomal storage disease caused by mutations in the 
gene MCOLN1, which codes for the transient receptor potential family ion channel TRPML1. 
MLIV has an early onset and is characterized by developmental delays, motor and cognitive 
deficiencies, gastric abnormalities, retinal degeneration and corneal cloudiness. The degenerative 
aspects of MLIV have been attributed to cell death, whose mechanisms remain to be delineated 
in MLIV and in most other storage diseases. Here we report that acute siRNA mediated loss of 
TRPML1 results in an upregulation and cytosolic leak of the lysosomal protease Cathepsin B 
(CatB). TRPML1 KD induces apoptosis, marked by increased Caspase-3 activity and 
cytochrome C release. Inhibition of either CatB or the proapoptotic protein Bax prevents 
TRPML1 KD mediated apoptosis. Bax inhibition did not affect CatB release, suggesting that 
Bax lies downstream of CatB release.  This is the first evidence providing a mechanistic link 
between acute TRPML1 loss and cell death.   
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2.2 INTRODUCTION 
TRPML1 is a member of the TRP family of ion channels. Unlike most TRP channels, 
TRPML1 and its relatives TRPML2 and TRPML3 primarily reside in the membranes of the 
endocytic pathway (1-6). TRPML1 localizes to the deeper compartments along the endocytic 
pathway (late endosomes and lysosomes), due to the presence of lysosomal targeting sequences 
on its N- and C-termini (5, 6). TRPML1 is an inwardly rectifying cation channel that is activated 
by low, typically lysosomal, levels of pH (7, 8). TRPML1 activation by PI(3,5)P2 (9), a lipid 
predominantly found in late endosomes and lysosomes, provides a physiological context for its 
localization suggesting that it is either activated by delivery to the lysosomes or that it serves as a 
sensor for PI(3,5)P2 rich compartments matching lysosomes and late endosomes for fusion. 
TRPML1 has been suggested to regulate fusion/fission of vesicles in the endocytic pathway (4, 
160, 168, 184), and/or some aspect of lysosomal ion homeostasis such as pH, Fe2+, or Zn2+ 
content (9, 162, 186, 214).  
TRPML1 downregulation due to mutations in the gene MCOLN1 results in the rare 
lysosomal storage disease MLIV (2, 11). The disease is associated with the buildup of storage 
bodies of largely unknown origin. MLIV has a profound neurodegenerative profile, which, in 
mouse models, has been linked to retinal degeneration and demyelination of corpus callosum, 
deep layer neocortex, and cerebellar white matter tracts (12, 13). Gastric abnormalities including 
degeneration of parietal cells and hypochlorhydria have also been reported in MLIV patients and 
model mice (180-182, 221). As with most lysosomal storage diseases, the mechanisms of cell 
death in MLIV are unclear. We have previously suggested that lysosomal deficiencies in MLIV 
and, perhaps, other storage diseases, lead to autophagic deficits and buildup of effete 
mitochondria, which may expose cells to pro-apoptotic effects of cell stimulation with Ca2+ 
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modilizing agonists (14). Autophagy deficits have been confirmed in MLIV and several other 
lysosomal storage models (210, 222-227). Nonetheless, the selectivity of cellular loss in storage 
diseases remains puzzling. We believe that the key to identifying the cell death pathways in 
lysosomal storage diseases lies in deconstructing the early events accompanying the loss of 
TRPML1 or other components of the endocytic pathway. This task is difficult to accomplish in 
cells cultured from patients due to the possible and, indeed, likely, contribution of secondary 
effects due to chronic accumulation of storage material.  
To delineate the early events associated with the loss of TRPML1, we used siRNA 
mediated KD to acutely downregulate TRPML1 in HeLa cells. A KD of PPT1, an enzyme 
mutated in another lysosomal storage disease, Infantile Neuronal Lipofuscinosis, was used as a 
comparative control (16, 17). We show that TRPML1 loss specifically causes, within 48 hours of 
KD, an upregulation and cytoplasmic release of the lysosomal protease CatB, followed by 
activation of pro-apoptotic caspase-3. Apoptosis in TRPML1 KD cells involved CatB as well as 
proapoptotic protein Bax. These results illustrate, for the first time, the early events leading to 
cell death in TRPML1 deficient cells.  
2.3 EXPERIMENTAL PROCEDURES 
Cell Culture: HeLa cells were maintained in DMEM (Sigma-Aldrich, St Louis, MO) 
supplemented with 7% FBS, 100 µg/mL penicillin/streptomycin, and 5 µg/mL Plasmocin 
prophylactic (Invivogen, San Diego, CA). For siRNA KD, antibiotic free media was used. 
Antibiotic free media supplemented with 100mM sucrose was used for sucrose treatments. 
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 siRNA-mediated KD: siRNA were designed as described previously (162) and 
custom synthesized as ON-TARGET plus constructs by Dharmacon (Lafayette, CO). The 
TRPML1 siRNA probe targeting the sequence 5'-CCCACATCCAGGAGTGTAA-3' in 
MCOLN1 was used for all TRPML1 KD. The PPT1 siRNA probe targeting the sequence 5'-
GGTACTCACATAAATGCTT-3' in PPT1 was used for all PPT1 KDs. Control siRNA #1 
(Sigma) was used as a negative control. 6-well plates were transfected using Lipofectamine 2000 
(Invitrogen Carlsbag, CA). 7-day long KDs were maintained by splitting cells every 3 days and 
retransfecting them in suspension. Transfections were performed as described by manufacturer’s 
protocol using 300 nM siRNA per well. All KDs were confirmed using SYBR-green based 
quantitative real-time RT-PCR and Western blot analysis.  
 Reverse Transcriptase and Quantitative qPCR: RNA was isolated from cell using 
Trizol (Invitrogen) according to the manufacturer’s protocol. cDNA was synthesized using the 
GeneAmp RNA PCR system (Applied Biosystems, Carlsbad, CA) with 2 μL oligo dT priming. 
qPCR was performed using 2 µL cDNA, 2X SYBR green (Fermentas, Glen Burnie, MD), and 5 
μL of 4 µM primer per 50 µL reaction. The amount of cDNA loaded was normalized to starting 
RNA concentrations, with a final concentration of 6 ng of RNA loaded per experimental well. 
Six-point standard curves were generated for each primer using 1:2 dilutions of cDNA and 
loading 2 μL per well. Dilutions started at 20 ng of starting RNA. The following Quantitect 
primer assays were used: ACTB (β-actin, QT00095431), and CTSB (CatB, QT00088641). cDNA 
for the following genes were amplified using the indicated primers (IDT, Coralville, IA);  
MCOLN1: Forward: 5’-TCTTCCAGCACGGAGACAAC-3’ 
Reverse: 5’-AACTCGTTCTGCAGCAGGAAGC-3’ 
PPT1: Forward: 5’-CCTGTAGATTCGGAGTGG TTTGGATT -3’ 
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Reverse: 5’-CAGGCGGTCCTGTGTGTACA-3’ 
All primers were designed to span exons and negative RT controls were tested to ensure 
amplification of cDNA only. qPCR was performed using the Standard Curve method on the 
7300 Real Time System (Applied Biosystems). Reactions were run on the following parameters: 
2 min at 50°C, 10 min at 95°C, and 40 cycles at 95°C for 15 seconds followed by 60°C for 1 
minute. All experimental samples were run in triplicate and normalized to a β-actin endogenous 
control. Microsoft Excel was used to generate standard curves and analyze qPCR results.  
 Western blot analysis: Cells were solubilized for 10 min at room temperature in a 
detergent solution (0.5 M EDTA pH 8.0, 1 M Tris pH 8.0, 0.4% deoxycholate, 1% NP-40 
substitute) containing protease inhibitor cocktail mix III (Calbiochem, Gibbstown, NJ) and 
centrifuged at 16,000 g for 5 min. The supernatant was collected and protein concentrations were 
determined using a Bradford assay. Protein was incubated at 100°C for 5 min in sample buffer 
containing 14% β-Mercaptoethanol. Equal amounts of protein were loaded on a 12.5% SDS-
PAGE precast Tris-HCl polyacrylamide gel (BioRad, Hercules, CA) for each experimental 
sample. Proteins were transferred to PVDF membrane (Millipore, Billerica MA) and blocked in 
10% NFDM for 1 hr. The following primary antibodies were used: monoclonal Cathepsin B 
(CA10 clone, Calbiochem, IM27L) at 1:250 dilution, polyclonal PPT1 (Sigma, SAB1400222) at 
1:250, polyoclonal Lysosomal Acid Lipase (Abcam, Cambridge MA, ab73445) at 1:500 dilution, 
monoclonal LAMP1 (H4A3 clone, Santa Cruz, Santa Cruz CA) at 1:1,000 dilution, monoclonal 
Cathepsin D (CTD-19 clone, Sigma), monoclonal HA (HA.C5, Abcam) at 1:500, monoclonal 
GAPDH (Millipore, Billerica, MA), monoclonal Cytochrome C (7H8.2C12 Clone, Invitrogen) at 
1:1000, and monoclonal β-actin (AC-15 clone, Abcam) at 1:5,000 dilution. HRP conjugated goat 
anti-mouse or anti-rabbit secondary antibodies (Amersham, Piscataway, NJ) were used at 
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1:20,000 and 1:5,000 dilutions respectively. Immunodetection was performed with the Luminata 
Forte HRP substrate (Millipore). Band densities were measured using ImageJ (Bethesda, MD). 
For measurement of TRPML1 KD, cells were transfected with siRNA as described above. After 
24 hr, 2 μg of HA-TRPML1 DNA was transfected into cells using Lipofectamine 2000 
(Invitrogen) as described by manufacturer’s protocol. Cells were then immunoblotted for the HA 
tag 24 hr later. 
 Radioactive synthesis and degradation: 2 days after siRNA knockdown, cells 
were starved for 30 min in media lacking cysteine and methionine. Cells were then labeled for 2 
h at 37°C with 100μCi/mL of Tran35S-label (MP Biomedicals, Solon, OH). Cells were chased 
with serum free DMEM media containing unlabelled cysteine and methionine. At indicated time 
points, cells were lysed using 1X detergent solution and labeled proteins were 
immunoprecipitated overnight at 4°C with the CatB monoclonal antibody (CA10 clone, 
Calbiochem, IM27L). Antigen-antibody complexes were collected using Pansorbin cells coated 
with Rabbit anti-mouse antibodies 24 h later. Pansorbin cells were washed 3 times in RIPA 
buffer, and then resuspended in 20 μL of 4X sample buffer, boiled for 3 min, and pelleted at 
16,000 x g for 2 min. Supernatant was run on a 12.5% gel. Dried gels were analyzed using a 
phosphorimager and analyzed using Quantity One software (BioRad). 
 CatB Secretion: One day after KD, cell media was replaced with 0.5% FBS 
antibiotic free media. Media was collected 24 h later and concentrated on Millipore 10K Ambion 
filters. Concentrated protein was subjected to western blot analysis as described above.  
 Membrane/Cytosolic Separation: Cells were prepared as described in the Abcam 
Subcellular Fractionation protocol. Cells were solubilized using sonication (9 watt, 15 pulses). 
Nuclear and mitochondrial fractions were removed by 800 and 10,000 x g spins, respectively. 
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The cytosolic and membrane fractions were separate using a 100,000 x g spin for 1 hour at 4°C. 
The supernatant (cytosolic fraction) was concentrated using Millipore 10K Ambion filters 
(Millipore). The membrane pellet was washed 3 times with subcellular fractionation buffer and 
solubilized in detergent solution. β-actin was used as a loading control for both fractions. 
GAPDH was used as a loading control for the cytosolic fraction and to measure cytosolic 
contamination of membrane fractions. LAMP-1 was used to measure membrane contamination 
of the cytosolic fraction.  
 Cathepsin B Activity: Cathepsin B activity was analyzed using the EMD 
Innozyme Cathepsin B detection kit (Calbiochem, CBA001) following the manufacturer’s 
protocol. The kit measures Cathepsin B activity using the substrate Z-Arg-Arg AMC 
(Benzyloxycarbonyl-L-arginyl- L-arginine-4-methylcoumaryl-7-amide), which fluoresces when 
cleaved. Fluorescence was measured using a fluorometer, at an excitation wavelength of 360 nm 
and an emission wavelength of 440 nm. Pre-cleaved substrates were used to create AMC 
standard curves and fluorescence in experimental samples was plotted against these curves to 
determine concentrations (in μM) of cleaved AMC. All values were normalized to the total 
protein load.  
 Confocal and Electron Microscopy: Confocal and electron microscopy was 
performed as previously described (162). Cellular inclusions were classified as vacuoles that 
showed a multimembranous or a dense profile. Size of inclusions was not a determining factor 
and the profiles of inclusions included in these counts are displayed in Figure 4.6. The following 
primary antibodies were used: monoclonal anti-TFEB (Abcam, ab56330), polyclonal anti-Lamin 
B1 (Sigma, SAB2101352), monoclonal LAMP-1 (H4A3 clone, Santa Cruz), and polyclonal Bax 
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(N-20, Santa Cruz). For indirect detection, a goat anti-mouse and goat anti-rabbit secondary 
antibodies from Invitrogen were used.  
 Apoptosis assay:  Cells were prepared and measured using the EnzChek Caspase-
3 Assay Kit #1 (Invitrogen) following the manufacturer’s instructions.  AMC substrate 
fluorescence was measured using a fluorometer at an excitation wavelength of 342 nm and an 
emission wavelength of 441 nm. 
 Statistical significance was calculated using a one-tailed, unpaired t-test with 
p≤0.05 considered significant. Data are presented as mean±S.E.M.  
2.4 RESULTS 
2.4.1 TRPML1 and PPT1 KD 
 Figs 2.1A,B show that our siRNA-mediated KD protocol resulted in a significant 
decrease in TRPML1 or PPT1 mRNA levels (a decrease of 78.0%±8.6 and 98.3%±3.7 
respectively, p<0.001, n=8) 48 h after transfection of HeLa cells. Knockdown was verified using 
Western blot analysis of heterologously expressed recombinant HA-tagged TRPML1 or 
endogenous PPT1 (Figs 2.1A,B). Commercially available antibodies to TRPML1 do not work or 
result in extremely dirty blotting profiles, therefore we used HA-tagged TRPML1 to visualize 
KD. Cellular inclusions have been previously shown to accumulate in the same TRPML1 KD 
model, further confirming that this model represents the early stages of MLIV (162). Electron 
micrographs of PPT1 KD cells also show large numbers of cellular inclusions. Therefore siRNA-
mediated PPT1 KD is an effective model of lysosomal dysfunction (Fig 2.1C).  
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Figure 2.1 siRNA-mediated downregulation of TRPML1 and PPT1 result in decreased mRNA and protein 
levels and recapitulate a storage defect phenotype.  
A) HeLa cells were transfected with TRPML1 siRNA 48 hr before collection. Total RNA was isolated and cDNA 
was synthesized and probed using TRPML1 specific exon-spanning primers. For protein detection, cells were 
transfected with N-terminally tagged HA-TRPML1 DNA 24 hr after siRNA transfection. Whole cell lysates were 
collected 24 hr later and subjected to Western blot analysis, probing for HA. The 37 kD band represents the N-
terminal HA-tagged cleaved fraction of TRPML1. All protein and mRNA levels were normalized to β-actin. B) 
PPT1 mRNA and protein levels were measured 48 hr after siRNA transfection as described above. Arrow represents 
mature form of PPT1. C) Cells were collected and fixed for EM images 48 hr after siRNA transfection. Scale bar 
represents 1 μm. Right panel represents a zoom-in image of the area on the left panel indicated by the black square. 
*, p<0.05, n=8 for both A and B. 
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2.4.2 CatB buildup in TRPML1 KD cells 
CatB is a ubiquitous lysosomal protease, which previously has been implicated in cell 
death upon lysosomal permeabilization. It has been shown that CatB released into the cytoplasm 
is active and promotes cleavage and activation of caspases involved in apoptosis (136, 137, 155, 
228, 229). To determine whether TRPML1 KD had an effect on CatB levels, we performed 
Western blot analysis on control and TRPML KD HeLa cells using CatB antibodies. Cell lysates 
were collected 48 h after siRNA transfection. All protein levels were normalized to β-actin 
loading controls. Figs 2.2A,B show that TRPML1 KD results in a robust increase of pro- and 
mature CatB levels whereas intermediate CatB (Int. CatB) levels are unaltered. CatB is 
processed through the ER and Golgi (intracellular CatB intermediates are seen as multiple bands 
in Western blots) and enters the endocytic pathway as an inactive zymogen (proCatB), which is 
autocatalytically cleaved by the active enzyme into its mature form (144). ProCatB and mature 
CatB levels increased by 213.3%±9.2 and 81.0%±16.5 (p<0.01, n=4 each) respectively in 
TRPML1 KD cells.  
In contrast to CatB, lysosomal acid lipase (LAL) levels decreased in TRPML1 KD cells 
(Fig. 2.2A,B; 32.5%±13.3 decrease, p<0.05, n=7), whereas LAMP-1 levels increased 
(72.4%±11.7 increase, p<0.01, n=3).  The changes in LAMP1 levels are consistent with previous 
studies showing that lysosomal markers are increased in LSDs (13, 227). Cathepsin D (CatD) 
levels did not change in TRPML1 KD cells (Fig 2.2A,B) indicating that the effect of TRPML1 
KD on CatB is specific.   
The physiological significance of CatB upregulation in TRPML1 KD HeLa cells was 
evaluated using the Innozyne CatB Activity Assay. CatB activity was upregulated by 
60.4%±15.6 (p<0.05, n=5) in TRPML1 KD whole cell lysates (Fig 2.2C), supporting the 
 43 
upregulation of mature CatB seen in our Western blot results demonstrating that the mature, 
active form of CatB is upregulated as a consequence of TRPML1 loss.  
 
 
Figure 2.2 TRPML1 KD and PPT1 KD specifically alter steady state protein levels of CatB, LAL, and 
LAMP-1.  
A, B) Representative Western blot (A) and blot density analysis (B) of HeLa whole cell lysates 48 hr after siRNA 
transfection show increased CatB and LAMP-1 levels, and decreased LAL levels in TRPML1 KD cells. CatD levels 
did not seem to change in TRPML1 KD cells. C) CatB activity was measured using the EMD Innozyme Cathepsin 
B detection kit. Precleaved AMC substrates were used to create a 6-point standard curve, μM AMC were determined 
using this curve. Values were normalized to total protein load. *p<0.05, n=5. D, E) Representative Western blot (D) 
and blot density analysis (E) of PPT1 KD cells shows an increase in proCatB not mature CatB, LAL, or LAMP-1. 
Lanes containing control and PPT1 KD samples were not run in continuous lanes, which is denoted by dividing line 
in CatB and LAMP-1 blots. *p<0.05, n≥3. 
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To test whether TRPML1 KD induced changes of CatB and LAL levels were caused by 
general endocytic inhibition, HeLa cells were treated for 48 h with the lysosomal inhibitors 
BAPTA-AM (162), a Ca2+ chelator which inhibits fission/fusion events and results in membrane 
trafficking defect; bafilomycin A1, an inhibitor of the lysosomal H+ ATPase pump that blocks 
the acidification of lysosomes (61); or leupeptin, a serine/cysteine protease inhibitor which 
prevents degradation of protein substrates in the lysosome (230, 231). These inhibitors did not 
alter LAL levels and did not result in CatB increase (Figure 2.3), suggesting that these changes 
are TRPML1 KD specific. 
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Figure 2.3 Increased levels of CatB and decreases LAL levels are TRPML1 specific and not due to general 
endocytic disruption.  
HeLa cells were treated with the endocytic inhibitors BAPTA-AM (10 μM), bafilomycin A1 (10 nM), and leupeptin 
(10 μM) for 48 h. These inhibitors did not affect LAL levels and did not lead to a CatB increase. Therefore, general 
endocytic disruption does not cause protein changes similar to that of TRPML1 and PPT1 KD. *p<0.05. n≥5. 
 
Finally, we analyzed LAMP1, CatB, and LAL levels in PPT1 KD to determine if the 
changes we observe are specific to TRPML1 KD. LAL and LAMP-1 levels are unaffected in 
PPT1 KD cells (Figs 2.2D,E). We did observe a 107.8%±21.9 (p<0.05, n=3) increase in proCatB 
levels, however there was no significant increase in mature CatB levels in PPT1 KD cells. These 
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results suggest that PPT1 KD affects the automaturation of the inactive CatB zymogen. There 
was no significant change in LAMP1 (n=3, p=.4) or LAL (n=3, p=.1) levels in the PPT1 KD 
cells.  Therefore, downregulation of the genes MCOLN1 and PPT1 affects protein levels of 
specific lysosomal components.  
CTSB, the gene coding for CatB, is a member of the CLEAR gene network regulated by 
TFEB transcription factor, as are genes coding for LAL and LAMP-1.  Genes in this network are 
upregulated upon increased TFEB expression and nuclear translocation (18). Although the 
CLEAR network was clearly shown to coordinate changes in genes coding for lysosomal 
proteins, input signals regulating it are currently unclear. To determine if the CLEAR network 
was activated in our system as well as inducing changes in gene expression, we measured mRNA 
levels of CatB, LAL, and LAMP1.  There was no significant change in CatB, LAL, and LAMP1 
mRNA levels in TRPML1 and PPT1 KD cells compared to control cells within 48 h of KD (Fig 
2.4A). Values were normalized to β-actin mRNA levels. Western blotting and confocal 
microscopy show no change in TFEB protein levels or localization in TRPML1 KD cells (Figs 
2.4B,C). Therefore, CatB upregulation in the acute KD model likely takes place at the post-
transcriptional level and the TFEB driven lysosomal gene network is not activated in response to 
this KD.  
To confirm that the TFEB gene network reports the functional status of lysosomes in our 
experimental system, we used protocols previously used to establish this paradigm. First, 
incubation of cells with 100 mM sucrose, previously shown to disrupt lysosomal traffic and 
stimulate the TFEB network (18), was performed and the transcriptional levels of CatB, LAL, 
and LAMP1 were analyzed using qRT-PCR. Fig 2.4D shows that 2 and 5 day sucrose treatments 
induce an increase in levels of these TFEB regulated genes, consistent with previous studies. 
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Prolonged (7 days) TRPML1 KD in HeLa cells is associated with an increased buildup of 
storage bodies (162). We reasoned that if the TFEB network reports the general disruption of the 
lysosomal function and/or buildup of storage bodies, then the genes belonging to the TFEB 
network would be upregulated after prolonged TRPML1 KD. Fig 2.4E shows that 7 day KD of 
TRPML1 or PPT1 results in upregulation of CatB and LAL mRNA (CatB levels respectively: 
67.3%±14.2, 86.5%±12.1.  LAL levels respectively: 63.7%±5.0, 66.1%±7.8.  n=3, p<0.01). 
Since both genes belong to the TFEB network, we conclude that TFEB activation probably 
depends on general lysosomal cues such as storage bodies. It is interesting to note that LAMP1 
mRNA is not changed in this model, suggesting that additional stimulation cues are necessary to 
change expression of this gene. The elevated level of LAMP1 expression in our sucrose 
treatment appears to be time dependent (Fig 2.4D), suggesting that increased lysosomal 
dysfunction may be required for increases in LAMP1 gene expression. These results indicate that 
the biochemical events leading to CatB upregulation precede the critical juncture in lysosomal 
dysfunction that is necessary for activation of the CLEAR network.  
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Figure 2.4 TFEB regulated lysosomal genes and TFEB levels are unaltered in acute TRPML1 and PPT1 KD 
cells.  
A) mRNA levels were measured in TRPML1 and PPT1 KD cells using qRT-PCR using CatB, LAL, and LAMP-1 
specific primers. n≥3. No significant change was seen in mRNA levels under either condition. B) TFEB protein 
levels were measured by Western blot analysis in TRPML1 KD cells. No difference was seen. C) TFEB cellular 
localization was analyzed by confocal microscopy. No change in localization occurs after 48 hr of TRPML1 KD. 
n=3. D) qRT-PCR analysis of CatB, LAL and LAMP1 mRNA in HeLa cells exposed to 100 mM sucrose for 2 or 5 
days to induce general inhibition of the lysosomal function as described before. E) qRT-PCR analysis of the same 
genes in cells after 7-day KD of TRPML1 or PPT1. β-actin was used as a loading control. *p<0.05, n=3. 
  
Taken together, the results described above show upregulation of proCatB and mature 
CatB shortly after TRPML1 KD. The buildup of proCatB in both TRPML1 and PPT1 KD cells 
can be explained by general lysosomal malfunction leading to delayed processing of CatB. 
However, upregulation of the mature form of CatB appears to be TRPML1 specific and, under 
the conditions of acute TRPML1 KD, it is not caused by changes in gene expression.  
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2.4.3 CatB release in TRPML1 KD cells 
Lysosomal proteases have been implicated in cell death via the apoptosis program due to 
their release into the cytoplasm and activation of apoptotic caspases (136, 204, 232, 233). 
Several mechanisms of CatB release have been proposed. Some studies suggest general loss of 
lysosomal integrity, while in some studies lysosomes appear intact during the cytosolic CatB 
increase, suggesting a specific mechanism of CatB release. Since MLIV has a neurodegenerative 
profile, ostensibly due to neuronal loss, CatB changes in TRPML1 deficient cells may shed new 
light on cell death caused by MLIV. To elucidate the mechanism of CatB increase, we examined 
the degradation, synthesis, and cellular localization of CatB in TRPML1 KD cells. 
To determine whether TRPML1 KD induced CatB upregulation is caused by increased 
protein synthesis or decreased degradation, cells were pulsed with 35S labeled cysteine-
methionine for 2 h then chased with serum-free media for 0, 3, 6, 9, and 12 h. Whole cell lysates 
were collected at each time point and 35S-CatB was immunoprecipitated, and visualized on a 
SDS-PAGE gel. A small aliquot of lysate was collected and subjected to Western blot analysis to 
measure β-actin levels; all values were normalized to β-actin. There were no appreciable 
differences in CatB synthesis, as measured at the 0 hour time point (Fig 2.5A). Cell lysates were 
collected, immunoprecipited with CatB antibody, and subjected to Western blot analysis 30, 60, 
90, and 120 min during labeling, to ensure that labeling is linear (data not shown). Furthermore, 
there was little difference between CatB degradation rates in control and TRPML1 KD cells (Fig 
2.5B).  Therefore, translation and degradation of CatB is unaffected in TRPML1 KD cells.   
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Concentrated proteins in the medium were subjected to Western blot analysis to measure 
CatB secretion. There was an 83.8%±18.2 (p<0.01, n=3) increase in extracellular Intermediate 
CatB in TRPML1 KD cells, normalized to extracellular β-actin (Fig 2.5C), however there was no 
difference in extracellular levels of proCatB. The increase in intracellular levels of proCatB, but 
the lack of increase in the extracellular media, suggests that proCatB secretion is impaired in 
TRPML1 KD cells and may contribute to the buildup of intracellular CatB.  
 51 
 
Figure 2.5 Levels of CatB activity and secreted proCatB are elevated in TRPML1 KD cells.  
Degradation and synthesis is unaffected in these cells. A) Synthesis of 35S-CatB was measured beginning 
immediately after a 2 hr labeling period. Levels were normalized to β-actin. n=3. B) Degradation rates of CatB were 
measured over a 12 hr time course. 35S-CatB levels were normalized to β-actin and rates of degradation were 
determined using a linear fit curve. C) Levels of CatB secretion were measured by Western blot analysis. Higher 
levels of proCatB are detected in the media but are several fold less than intracellular proCatB levels. *p<0.05, n=3. 
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Cytosolic release of CatB has been demonstrated in several studies.  Previous studies 
demonstrated CatB localization through the expression of GFP-CatB whereas others established 
endogenous CatB localization using fractionation assays (59, 136, 154, 234).  Despite numerous 
attempts we were unable to clearly visualize endogenous CatB in HeLa cells.  Since our data 
focuses on endogenous CatB dynamics we established CatB localization using 
cytosolic/membrane fractionation.  Fractions from control and TRPML1 KD cells were isolated 
and CatB, LAMP-1, GAPDH, and β-actin were compared in these fractions. GAPDH was only 
detected in the cytosolic fractions while LAMP-1 was only detected in the membrane fraction 
(Fig 2.6A), confirming specificity of our preparation. β-actin was used to normalize CatB and 
LAMP-1 levels in our membrane fractions. GAPDH was used to normalize CatB in the cytosolic 
fractions. Our data show a significant increase of CatB in both fractions (Figs 2.6B,C) and 
increased LAMP-1 levels in membrane fractions (Fig 2.6C). These data are consistent with our 
whole cell analyses.  
Interestingly, cytosolic proCatB levels increased 366.8%±31.6 (p<0.01, n=3) in TRPML1 
KD cells, suggesting that a large amount of CatB is released into the cytosol.  Overall, we 
suggest that decreased CatB secretion may result in high intracellular levels, combined with the 
release of CatB into the cytosol in TRPML1 KD cells. 
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Figure 2.6 TRPML1 KD results in high levels of cytosolic and membrane associated CatB.  
A) Cytosolic and membrane fractions were isolated from HeLa lysates through differential centrifugation 48 hr at 
TRPML1 KD and identified using GAPDH and LAMP-1 antibodies. B) Cytoplasmic fractions. CatB levels were 
measured by Western blot analysis and normalized to GAPDH. C) Membrane fractions show increases in CatB and 
LAMP-1 levels, consistent with whole cell lysate analyses. Due to changes in LAMP-1 levels, β-actin was used as a 
loading control for both CatB and LAMP-1 quantification. *p<0.05, n=3. 
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2.4.4 CatB and apoptosis in TRPML1 deficient cells 
Leakage of CatB and other lysosomal proteases into the cytosol has been shown to lead 
to apoptosis (235-239). This phenomenon seems to take place in our system as well. Apoptosis 
levels were tested in control and in TRPML1 and PPT1 KD cells using a Caspase-3 (Cas3) 
fluorogenic substrate assay. Apoptosis was significantly upregulated in TRPML1, but not in 
PPT1 KD cells (Fig 2.7A). Western blot analysis revealed cytosolic cytochrome C release in 
these cells (Fig 2.7B), a positive marker of apoptosis.  In TRPML1 KD cells, Cas3 activity 
averaged 162.9±9.3% of its value in control cells, while in PPT1 KD cells it averaged 
107.31±4.7% of control values (n=3 for each set of conditions; p<0.01 for TRPML1 KD cells). 
24 hour incubation of control and TRPML1 KD cells with the cell-permeable CatB inhibitor Ca-
074Me (2.5 µM) resulted in decreased apoptosis in TRPML1 KD cells as compared with 
untreated control (67.9±7.2%, p<.01, n=3).  Ca-074Me did not alter apoptosis in control treated 
cells as seen in Fig 2.7A. This suggests that apoptosis in TRPML1 KD cells is CatB dependent 
and that apoptosis is an early specific consequence of TRPML1 loss.  
The proapoptotic protein Bax has been implicated in CatB release in several systems 
(136, 155, 240, 241). Fig 2.7B shows that 24 hour treatment with Bax inhibiting peptide (100 
µM, Calbiochem) prevented apoptosis in TRPML1 KD cells without significantly affecting 
apoptosis rates in control cells, suggesting that this effect is specific to TRPML1 KD dependent 
apoptotic processes. Inhibition of Bax had varied results on cytoplasmic CatB levels, actually 
increasing CatB in control cells treated with the inhibitor.  TRPML1 KD cells treated with the 
inhibitor had significantly elevated cytoplasmic CatB levels compared to both untreated and Bax 
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inhibited control cells as seen in Figure 2.7C (n=4, p<.01, p=.05 respectively).  These data 
suggest that CatB release lies upstream of Bax. Confocal microscopy of TRPML1 cells showed 
punctate Bax staining (red) as compared to control cells, which did not overlap with the 
lysosomal marker LAMP1 (green) (Fig 2.7D)  These observations are in agreement with 
previous studies, which indicate Bax translocation to punctate mitochondria and cytochrome 
release in Cathepsin/Bax-dependent apoptosis (58).  Further studies will focus on elucidating 
these pathways and determining the sequence of events that leads to Bax activation, Caspase-3 
activation, and apoptosis in these cells. 
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Figure 2.7 TRPML1 KD results in cell death via Bax and CatB dependent mechanism.  
A) Apoptosis was measured using the EnzChek Caspase-3 Apoptotic assay 48 hr after TRPML1 and PPT1 KD. Ca-
074Me (2.5 µM) was added 24 hr after KD. *p<0.01 of untreated control, n=3. B) Caspase-3 activity was measured 
in TRPML1 KD cells 48 hr after KD in the presence and absence of Bax inhibiting peptide (100 µM, added 24 hr 
after KD). *p<0.05, n≥3. Western blot analysis of cytosolic fractions revealed an increase in the pro-apoptotic 
marker Cytochrome C in TRPML1 KD cells as compared with control.  C) Western blot example and statistical 
analysis of CatB in 48 hr TRPML1 KD cells treated with Bax inhibiting peptide (100 µM, added 24 hr after KD). 
*p<0.05, n≥3.  D) Confocal microscopy of Bax localization reveals punctate localization in TRPML1 KD cells, 
which did not overlap with LAMP1 staining.   
2.5 DISCUSSION 
The present study shows that shortly after TRPML1 KD in HeLa cells, the lysosomal 
protease CatB is translocated into the cytoplasm where it triggers cell death through apoptosis. 
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Apoptosis is set in motion by a CatB dependent mechanism that involves the pro-apoptotic 
protein Bax. These data are in line with previous reports on lysosomal toxicity (136, 137, 155, 
228, 229, 235-241). They do, however, raise several important questions relevant to lysosomal 
storage diseases and lysosomal function.  
Cell death clearly underlies the key degenerative aspects of lysosomal storage diseases. 
Its mechanisms in lysosomal storage disorders, however, are not well understood. Some of the 
current models, including suppressed flow of key substrates or accumulation of effete organelles 
due to autophagy block, have been discussed (30, 209, 223). Here we showed that in addition to 
the “supply side” issues in lysosomal storage diseases, an active and early CatB release 
mechanism specifically caused by TRPML1 loss takes place soon after TRPML1 KD. Relative 
contribution of each of these mechanisms in cell death in specific tissues remains to be 
established. It is, however, likely that if the propensity for CatB release varies between different 
tissues, then the CatB release mechanism may explain tissue specific cell death in lysosomal 
storage diseases.  
The mechanism of CatB release in TRPML1 KD cells remains to be identified. Cytosolic 
CatB release has been implicated in many instances of cellular toxicity, including those caused 
by cytoplasmic/ mitochondrial and by lysosomal events (235-239). Dissociation of lysosomal 
membrane by lysosomotropic agents has been proposed as one explanation for this phenomenon. 
It is important to note that nonselective physical damage to the lysosomal membrane is usually 
associated with a general loss of lysosomal integrity and release of a number of lysosomal 
components, including lysosomal dyes, into the cytoplasm. This has not been observed in our 
system; indeed the lysosomal component CatD does not appear to change in TRPML1 KD cells 
(Fig 2.2). We do not detect any measurable loss of lysosomal integrity using the lysosomal 
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marker lysotracker (not shown). These observations are in line with previous findings of CatB 
translocation into cytoplasm without detectable loss of lysosomal integrity. Bax is involved in 
permeability pore transition in mitochondria, which triggers apoptosis; however several studies 
clearly implicated it in lysosomal permeabilization by direct interaction with lysosomes or with 
another non-mitochondrial membrane fraction (232, 242-245). However, our results did not 
show a significant decrease in cytosolic CatB levels after Bax inhibition, suggesting that this 
protein lies downstream of CatB release.  As TRPML1 KD does not seem to induce gross 
dissociation of lysosomal membrane, it is tempting to speculate that other pro-apoptotic 
molecules such as caspase-8 induce a specific CatB release route to assist or initiate apoptotic 
events. Elucidating these pathways will provide a clearer understanding of the consequences of 
TRPML1 KD that result in cell death. 
 It is important to remember that Bax has been implicated as a pro-apoptotic 
signal. The relation between TRPML1 KD, CatB release, apoptosis and Bax is a subject of future 
investigation. One possible mechanism could involve lysosomal deficiencies caused by 
TRPML1 KD inducing pathways that activate Bax, which initiates CatB release followed by 
caspase cleavage. Alternatively, CatB release could be a “cleanup” event, taking place 
downstream or in parallel with apoptosis caused by Bax activation.  
One interesting observation is that TRPML1 has been shown to be cleaved by CatB in the 
lysosome (1).  If the cell monitors the loss of TRPML1 activity, it could be that CatB cleavage of 
TRPML1 mediates this activity and is therefore a direct cellular response to TRPML1 loss, 
which results in downstream off-target effects such as apoptosis.  Future studies will be 
conducted to determine if CatB mediated TRPML1 cleavage modulates the activity of the 
channel and whether loss of TRPML1 activity itself is enough to potentiate CatB upregulation. 
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3.0   ACUTE DOWNREGULATION OF LYSOSOMAL GENES SPECIFICALLY 
AFFECTS TRANSCRIPTION OF GENES OUTSIDE THE “CLEAR” NETWORK 
3.1 ABSTRACT 
Lysosomal storage diseases (LSDs) are rare disorders caused by mutations in the genes 
coding for components of the endocytic pathway. Their defects result in the buildup of inclusions 
containing undigested substrates and in cell death, manifesting clinically as a range of conditions 
that include developmental delays, loss of motor function, retinal degeneration and corneal 
opacity. It is becoming increasingly clear that the effects of LSDs reach beyond the accumulation 
of undigested substrates and involve gene and protein networks. It is thus possible that the 
pathogenesis of LSDs may involve processes not directly related to the root cause of the disease 
but rather the changes induced by the downstream cellular responses, such as transcriptional 
changes. To elucidate the early transcriptional responses set in motion by LSDs, we induced 
acute downregulation by siRNA-mediated KD of proteins linked to LSDs such as the ion channel 
mucolipin-1 (TRPML1) and the enzyme palmitoyl-protein thioesterase 1 (PPT1), which are 
defective in mucolipidosis type IV and infantile neuronal ceroid lipofuscinosis 1, respectively. 
We analyzed changes in transcription 48 h after KD using microarray analyses. We found that 
specific subsets of genes are affected by TRPML1 and PPT1 KD and these genes appear to be 
regulated by a small set of transcription factors.  In TRPML1 KD a high percentage of genes 
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altered are associated with the transcription factor NFκB, which is upregulated upon TRPML1 
loss.  These findings suggest that loss of lysosomal proteins activate specific transcriptional 
pathways.  Further elucidation of the transcription factors and pathways activated by TRPML1 
and PPT1 loss may shed light on the early consequences of losing these proteins as well as 
explain the downstream cellular responses. 
3.2 INTRODUCTION 
How do cells assess the functional status of their endocytic pathway and do they actively 
respond to the changes in its function?  Is it possible that cellular responses to LSDs reach 
beyond the endocytic pathway and factor in to the pathogenesis of LSDs?  To address these 
questions, we have examined alterations in gene expression upon loss of genes implicated in 
LSDs, measuring the immediate cellular response to loss of endocytic components.  Recently 
published evidence suggests existence of a lysosomal gene network driven by the transcription 
factor (TF) TFEB, which regulates the expression of genes whose regulatory elements contained 
a well-defined “CLEAR” sequence (18). It was suggested that TFEB orchestrates the expression 
of lysosomal proteins for lysosomal biogenesis and perhaps in response to disturbances in the 
endocytic pathway, including chronic cell models of LSDs (18). This attractive model and the 
previous reports on changes in gene expression in LSDs suggest active cellular monitoring of 
endocytic integrity (220, 246).  
It is not clear whether TFEB is the only means of coordinating the expression of 
lysosomal proteins or whether the TFEB regulated lysosomal network interacts with other 
cellular regulatory circuits. It is possible, and, indeed, likely that the cellular program of 
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endocytic monitoring involves processes both directly involved and unrelated to lysosomal 
function. It is also possible that some of the cellular changes induced in response to endocytic 
deficiencies may contribute to disease pathogenesis. Towards delineating such responses, we 
performed gene expression analyses in cells with acute deficiencies of the important endocytic 
components TRPML1 and PPT1. The loss of either protein results in LSDs however their 
function in the lysosome is unrelated, allowing us to compare how cells respond to the loss of 
different types of endocytic components (1, 7, 186). We performed microarray analyses 48 h  
after siRNA-mediated KD of TRPML1 and PPT1 in HeLa cells to separate changes induced 
directly by the loss of these proteins from those induced by the buildup of the undigested 
material, which occurs in chronic LSD cell models (247, 248).  
TRPML1 is an ion channel coded by the gene MCOLN1 (2). TRPML1 is a member of the 
TRP family of ion channels and is localized in lysosomes and late endosomes (1, 2).  
Physiological readings demonstrate that TRPML1 is permeable to mono- and divalent cations 
and that permeation through a constitutively active form of TRPML1 is stimulated by low pH (1, 
7, 8). Recently, TRPML1 was shown to be activated by PI(3,5)P2 and previous reports 
demonstrating its ability to conduct Ca2+, supports its role in Ca2+-driven, SNARE-dependent 
membrane fusion in the endocytic pathway (7, 10). Another model for TRPML1 function 
suggests a role in the modulation of lysosomal ion homeostasis and, therefore, digestive function, 
by regulating the lysosomal Fe2+ load or pH (162, 188).  
Neuronal ceroid lipofuscinoses (NCL) are a class of diseases collectively referred to as 
Batten disease. Each NCL is caused by the loss of a specific lysosomal enzyme. The loss of 
PPT1 results in infantile neuronal ceroid lipofuscinosis (INCL) and is the most severe NCL 
(249). PPT1 is responsible for the cleavage of fatty acids from lysosomal protein substrates and 
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the buildup of undigested substrates in PPT1 deficient cells is associated with stunted growth, 
cognitive dysfunction, blindness and an abbreviated lifespan. The amount of PPT1 activity lost 
in INCL correlates with the severity of the disease, directly linking the activity of this enzyme 
with the disease pathogenesis (250). Studies have suggested both lysosomal as well as synaptic 
vesicle localization of PPT1, suggesting that it may play a role both in the endocytic pathway 
and extracellularly (251, 252). The differences between protein function and localization of 
PPT1 and TRPML1 allow us to answer whether the cell can distinguish between specific 
endocytic components and respond accordingly or whether lysosomal malfunction will trigger a 
generalized response.  
Our results show that genes outside of the TFEB network are altered upon TRPML1 KD, 
and that these same genes are not affected by PPT1 loss. The genes affected in TRPML1 and 
PPT1 KD cells seem to share regulatory elements for a select subset of transcription factors.  A 
large percentage of genes affected in TRPML1 KD are associated with the transcription factor 
NFκB, which, is itself, upregulated upon TRPML1 loss. The genes altered in this study are not 
part of the “CLEAR” network.  This suggests that specific gene pathways are being altered upon 
TRPML1 and PPT1 loss and that these pathways are independent of the reported lysosomal gene 
network. Interestingly, the “CLEAR” network genes LAMP1, LIPA, and CTSB, which are 
unaltered 48 h after TRPML1 and PPT1 KD, are upregulated after 7 days of downregulation.  
These genes are also upregulated 48 h and 5 days after sucrosome formation.  This differential 
activation of “CLEAR” network genes suggests that higher degrees of lysosomal dysfunction 
may be driving the activation of this network.  This also suggests that there are different cues that 
activate the specific transcriptional changes we see in acute, “mild” lysosomal dysfunction 
compared to more robust dysfunction and demonstrates crosstalk between the endocytic pathway 
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and nucleus, through TF activity. Further work into dissecting these pathways and understanding 
the cascades that lead to transcriptional and lysosomal changes will help to elucidate how the cell 
monitors and responds to endocytic disruption and whether these responses directly affect 
disease pathogenesis. 
3.3 EXPERIMENTAL PROCEDURES 
Cell Culture: Cells were maintained as described in 2.3.  Antibiotic free media 
supplemented with 100mM sucrose was used for sucrose treatments. 
 siRNA-mediated KD: KDs were performed as described in 2.3. All KDs were confirmed 
before microarray analyses and confirmed using microarray readout of MCOLN1 and PPT1 
respectively. 
Microarray: Microarrays were performed using Illumina BeadChip® Human Whole 
Genome (WG-6) arrays for the TRPML1 analyses and Illumina HumanHT-12 v4 Expression 
BeadChip for the PPT1 analyses.  The microarrays and normalization was performed by the 
Genomic Core Laboratories at the University of Pittsburgh. 4 sets of control siRNA and PPT1 
siRNA samples were run in triplicate.  2 sets of TRPML1 siRNA samples were run in triplicate 
for this analysis. Data was normalized using the cubic spline method by the Core Laboratories.  
Cy3 emission values were normalized to control values to obtain changes in gene expression.   
RNA isolation, Reverse Transcriptase, and Quantitative qPCR:  All methods and primers 
used are described in section 2.3.   
Western blot analysis: Performed as described in section 2.3. Monoclonal NFκB 
p105/p50 (Abcam, ab7971) at 1:250, and monoclonal β-actin (AC-15 clone, Abcam) at 1:5000 
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were used for protein detection. HRP conjugated goat anti-mouse or anti-rabbit secondary 
antibodies (Amersham, Piscataway, NJ) were used at 1:20,000 and 1:1,500 dilutions 
respectively. Nuclear fractions were isolated using the Millipore Nuclear Extraction kit. 
Confocal Microscopy: As described in 2.3. The following primary antibodies were used: 
polyclonal NFκB p105/p50 (clone E381, Abcam), monoclonal anti-NPM (Invitrogen, 187288), 
polyclonal anti-Lamin B1 (Sigma, SAB2101352). For indirect detection, a goat anti-mouse and 
goat anti-rabbit secondary antibodies from Invitrogen were used.  
Statistical significance was calculated using a one-tailed, unpaired t-test with p≤0.05 
considered significant. Data are presented as mean±S.E.M.  
3.4 RESULTS 
3.4.1 Microarrays show specific gene changes in TRPML1 and PPT1 KD 
Limited proteomic and gene expression analyses of cell lines from LSD patients 
including an MLIV line have previously been performed (253, 254). However, these models are 
not well suited for studying the initial regulatory networks set in motion by the loss of endocytic 
components, as the chronic buildup of undigested material in these models may cause secondary 
effects, which may convolute, override, or mask the initial cellular responses. Therefore, acute 
KD models give us a unique opportunity to test the immediate effects of downregulating 
lysosomal components on gene expression.  As shown in section 2.4.2., several TFEB driven 
“CLEAR” network genes seem to be activated by high levels of endocytic disruption but not 
after acute downregulation of single lysosomal components.  Therefore, we suggest that 
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microarray analyses of TRPML1 and PPT1 acute KD cells will demonstrate transcriptional 
changes outside of the TFEB network. siRNA-mediated TRPML1 and PPT1 KD in HeLa cells 
was confirmed using quantitative real-time PCR (qRT-PCR) as described in section 2.4.2.  
Verified KD samples were sent for microarray analysis to the Genomic Core Laboratories at the 
University of Pittsburgh. TRPML1 KD mRNA levels were between 30-50% of control cells, 
PPT1 KD mRNA levels were ~10-30% of control cells. 
In our microarray assays, TRPML1 mRNA expression was decreased to between 29 and 
50% of control levels and PPT1 was decreased ~20% of control levels in all samples, consistent 
with the preliminary qRT-PCR results. Our microarray analysis identified close to 100 genes that 
were unidirectionally altered in two biological replicates.  The genes altered in our TRPML1 and 
PPT1 KDs were not associated with the TFEB network, confirming that acute downregulation of 
lysosomal components does not put enough stress on the endocytic pathway to activate this 
response.  In addition, the level of differential expression of these genes correlated with the 
efficiency of the knockdown, providing further evidence that these changes were a direct effect 
of TRPML1 or PPT1 KD.  For further analyses, we focused on genes that were decreased to less 
than 50% or increased to more than 150% of control levels in all samples.  Tables A.1,2 
(Appendix A) list the 32 genes altered in our TRPML1 KD and 71 genes altered in our PPT1 KD 
using this cutoff criteria.   
 
To further confirm our microarray analyses, we more closely examined two genes 
selected in the TRPML1 KD microarray using qRT-PCR.  The genes, LYPLA1 and CD83, are 
downregulated upon TRPML1 KD, but remain unaltered in PPT1 KD samples. These genes 
were selected because their products have been shown to either play a role in substrate 
degradation (LYPLA1) or be processed in the lysosome (CD83) (255, 256). qRT-PCR results 
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confirmed our microarray data, showing a 50.3%±23.5 decrease in LYPLA1 mRNA and a 
54.9%±11.3 decrease in CD83 (p<0.05, n=4, Fig 3.1A). There was no significant difference in 
LYPLA1 and CD83 mRNA between our control and PPT1 KD cells (Fig 3.1C). In addition, the 
measured mRNA resulted in similar protein changes. As seen in Figs 3.1B,D CD83 and 
LYPLA1 protein levels were decreased in TRPML1 but not PPT1 KD cells. Therefore, the loss 
of lysosomal components results in specific changes in gene expression.   
3.4.2 Regulatory analysis of TRPML1 KD suggests that changes in gene expression may 
be regulated by specific transcription factors  
As a preliminary analysis of our microarray data, we sought to determine if genes altered 
in the microarrays share common regulatory elements.  To do this, we used TF predictions made 
by SABiosciences' Text Mining Application and the UCSC Genome Browser (panel of over 200 
TF).  Using this database we found that our candidate genes are associated with at least 1 of 5 
TFs (ARNT, NRSF, CUTL1, NFκB, and PPAR-γ2 Fig 3.2A), suggesting that these TFs may 
play a major role in the regulation of our candidate genes in response to TRPML1 KD. NFκB is 
the most commonly associated TF in our panel (Fig 3.2A).  
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Figure 3.1 Candidate genes CD83 and LYPLA1 are downregulated in TRPML1 but not PPT1 KD cells. 
Candidate genes CD83 and LYPLA1 are downregulated in TRPML1 KD but not PPT1 KD cells. A,C)  Total RNA 
was isolated from cells 48 h after siRNA transfection. cDNA was synthesized and subjected to SYBR green based 
real-time PCR using β-actin, CD83, and LYPLA1 primers. mRNA levels of both CD83 and LYPLA1 are 
downregulated in TRPML1 KD cells. There was no significant difference between PPT1 and control siRNA gene 
levels. B,D)  Downregulation of CD83 and LYPLA1 mRNA levels resulted in decreased protein levels in TRPML1 
cells as assayed by Western blot analysis.  *, p<0.05. 
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Figure 3.2 Analysis of TRPML1 KD candidate genes reveals common subset of TFs which may regulate 
candidate gene expression, including NFκB. 
A) Identification of SABiosciences’ regulatory TF binding sites on genes downregulated by 50% or upregulated by 
150% or more in TRPML1 KD cells revealed 5 TFs that associate with these genes. B) p105/p50 NFκB which is 
associated with over 60% of these genes is upregulated in TRPML1 KD cells. *p<0.05, n=3. C,D) Confocal analysis 
reveals increased p105/p50 NFκB levels and nuclear translocation in TRPML1 KD cells.  Western blot analysis of 
nuclear and cytoplasmic extracts show increased nuclear translocation of NFκB in TRPML1 KD cells. 
 
3.4.3 NFκB is upregulated in TRPML1 KD cells and may regulate transcriptional 
changes  
Since NFκB is associated with the highest percentage of candidate genes in TRPML1 KD 
cells, we decided to look at transcriptional levels of this TF from our microarray.  We found that 
NFκB p105/p50 mRNA levels were elevated in TRPML1 KD cells (167% and 142% of control 
levels in each microarray).  Western blot analysis revealed an upregulation of the p105/50 
isoforms 48 hr after TRPML1 KD (Fig 3.2B).  Confocal analysis and nuclear extraction assays 
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blotting with p105/p50 NFκB-specific antibodies showed upregulation and nuclear translocation 
of NFκB in TRPML1 KD cells (Figs 3.2C), suggesting that NFκB plays a role in TRPML1 KD 
induced gene expression changes. NFκB was unaltered in PPT1 KD cells (Fig 3.2B).  
3.4.4 Comparison of TRPML1 and PPT1 KD reveals common TFs associated with 
altered genes. 
In order to study regulatory networks controlling genes altered in our microarray 
analyses, we compared the TFs associated with our candidate genes from each analysis.  Since 
we do not see an overlap in the genes that are altered in these KDs, we wanted to determine if 
any common TF pathways may be activated, although their ultimate effect would be different.  
We find that there are several specific TFs associated with our candidate genes in each KD 
condition, however, we find that CUTL1, c-jun, GATA-1, and AP-1 are associated with a fair 
percentage of candidate genes from both microarrays (Fig 3.3).  This may suggest that these TFs 
are activated or repressed in both KD conditions.  Further work will have to be conducted to 
determine whether or not these TFs are regulating the altered genes, and whether common 
pathways are being activated in the KD conditions.  
 
 71 
 
Figure 3.3 Comparison of TFs associated with candidate genes in TRPML1 and PPT1 KD 
Using the SABiosciences' Text Mining Application and the UCSC Genome Browser, we compiled a list of TFs 
associated with 20% or more of our candidate genes.  We then compared our results in the TRPML1 and PPT1 KD 
cells. 
3.5 DISCUSSION 
We previously tested whether the length or degree of lysosomal dysfunction is driving 
“CLEAR” network changes through 2 and 5 day sucrosome formation as well as 2 and 7 day 
TRPML1 KD, as discussed in section 2.4.2.  We found that sucrosome formation led to 
upregulation of the “CLEAR” network genes LAMP1, LIPA, and CTSB and that 7 day TRPML1 
KD was able to induce upregulation of LIPA and CTSB.  These findings suggest that the degree 
of lysosomal dysfunction drives these transcriptional changes, rather than the length of the 
dysfunction.  This is supported by our current microarray results, which showed changes in 
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several genes, none of which belong to the “CLEAR” network in either KD condition. This 
preliminary analysis of the microarray data shows that several specific as well as common TFs 
are associated with genes altered in both TRPML1 and PPT1 KDs.  Interestingly, using this 
approach we have been able to identify that NFκB p50/p105 is transcriptionally upregulated and 
translocates to the nucleus after TRPML1 KD.  Understanding the pathway that regulates this 
change will be the focus of future studies in the lab.  Interestingly, Cathepsin B has been shown 
to cleave Caspase-1, which has been linked to the activation of NFκB and NFκB-inducing 
pathways (257, 258).  Therefore, it will be interesting to address whether Cathepsin B and 
subsequent Caspase-1 cleavage activates this pathway.  Preliminary data (not shown) suggested 
that NFκB upregulation may be Cathepsin B dependent, however there was some variation 
suggesting that optimization of Cathepsin B inhibition may be required to get a clear readout.   
It will be interesting to further analyze other TFs selected using this approach, such as c-
jun, which is associated with a large percentage of candidate genes from both microarrays and 
which, is itself, transcriptionally upregulated in both TRPML1 and PPT1 KDs (28% and 88% 
increase, respectively, data not shown).  Future work will include altering our “target” TFs, such 
as NFκB using chemical and siRNA downregulation and measuring changes in gene expression 
in our KD conditions.  If we can identify which TFs are modulating these genes, we can then 
begin to dissect the pathways which may be activated upon TRPML1 and PPT1 loss.  Future 
studies will hopefully give a clearer understanding of how the endocytic pathway functions and 
responses to changes. 
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4.0  TRPML3 BLOCK BY TRANSITION METALS 
4.1 ABSTRACT 
Chronic and acute exposures to transition metals cause a range of conditions such as liver 
and brain damage (201, 259). Transition metals enter cells through plasma membrane 
transporters and through endocytosis of extracellular medium, which includes free and bound 
forms of transition metals (65, 66, 196, 197). Toxic effects of transition metals are usually 
attributed to their ability to catalyze production of reactive oxygen species, leading to 
degeneration of organellar membranes and buildup of misprocessed material within the 
endocytic tract (201, 203, 260-266). Whether or not transition metals directly affect components 
of the endocytic machinery is not well understood. The recent identification of TRPML channels 
as critically important endocytic components responsible for ion fluxes through endocytic 
membranes suggests a new target for transition metal toxicity. Here we report that micromolar 
concentrations of Co2+, Cu2+, Ni2+ and Zn2+ block TRPML3, while Fe2+ is significantly less 
effective in blocking TRPML3. Treatment of cells with 100 uM concentrations of transition 
metals leads to the formation of inclusion bodies, suggesting that endocytic function is impaired 
by these treatments.  The varitint-waddler (Va) TRPML3 mutant and the homologous 
TRPML1V432P are insensitive to transition metal block. A cysteine residue near the channel pore 
contributes to TRPML3 sensitivity to transition metals and is conserved in TRPML1.  These data 
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suggest that TRPML1 and TRPML3 may be blocked by transition metals, which could lead to 
cell toxicity if cells are exposed to high levels of transition metals.  
4.2 INTRODUCTION 
Transition metals are a group of elements comprising, among others, Co, Cu, Fe, Ni and 
Zn. They play major roles in key cellular processes such as respiration and therefore, they are 
indispensable for proper cell function. At the same time, transition metal overdose is a well-
documented environmental hazard associated with food, water and air pollution caused by 
industry or by improper food storage and handling techniques (193, 261, 267-269). Acute and 
chronic exposure to high levels of transition metals induces degenerative processes in brain, liver 
and other tissues, manifesting as cirrhosis, gastroenteritis and dementia (201, 259).  
Studies of transition metal toxicity have, primarily, focused on their effects in the 
cytoplasm (260, 261). Upon entering the cytoplasm through dedicated plasma membrane 
transporters such as Ctr1 (Slc31a1) (196, 197), or via the lysosomal route discussed below, 
transition metals catalyze production of reactive oxygen species (ROS), particularly in the 
mitochondria. The ROS destabilize mitochondrial membranes, resulting in release of cytochrome 
C, followed by cell death (260, 261). Hence, the wide use of metal chelation and neutralization 
of ROSs as treatments for metal toxicity.  
In a majority of tissues, transition metals first enter cells through endocytosis of metal 
binding proteins such as ceruloplasmin and transferrin. Liberation of transition metals from the 
binding proteins in lysosomes is followed by metal absorption in the cytoplasm via transporters 
such as Slc11a2 (also called DMT1, NRAMP2) (65, 66) and, perhaps, other ion channels and 
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transporters. In the lysosomal lumen, transition metals catalyze Fenton reactions, resulting in the 
buildup of ROS, which in turn, facilitate production of indigestible material such as lipofuscin. 
Lipofuscin buildup in the lysosomes has been linked to autophagic and mitochondrial 
abnormalities in aging cells (262-264).   
When the metal uptake exceeds the clearing capacity, lysosomes become overloaded with 
transition metals. The overload can occur due to abnormally high dietary metal uptake or genetic 
disorders of metal handling. It is important to note that metal overload frequently manifests as a 
buildup of undigested material captured during endocytoisis and retained in cytoplasmic storage 
bodies, a condition known as lysosomal storage disease. For example, liver samples of human 
and mouse Cu2+ overload models showed inclusions similar to those in lysosomal storage 
diseases (201, 203). It is unlikely that the storage phenotype in transition metal toxicity models is 
exclusively a function of lipofuscin buildup. Indeed, a multitude of factors including ion 
channels and transporters coordinate the endocytic function. Among the lysosomal components 
whose inhibition by transition metals may lead to this storage phenotype are TRPML ion 
channels (270-272).  
Several aspects of endocytic function depend on ion channel activity. They include 
regulation of lysosomal acidity, Ca2+ release driving organellar fusion and, quite likely, 
absorption of metal ions across the lysosomal membrane (30, 32). This list is likely incomplete, 
as demonstrated by the relatively recent identification and characterization of the ion channels 
TRPML1 and TRPML3. The gene MCOLN1 coding for TRPML1 is mutated in the lysosomal 
storage disease mucolipidosis type IV (MLIV) (273, 274). MLIV is a major lysosomal 
deficiency associated with cytoplasmic buildup of storage bodies, developmental delays and 
motor retardation. Due to its lysosomal localization, TRPML1 is assumed to have a role in the 
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lysosomal function, presumably in regulation of lysosomal ion homeostasis (pH, Fe2+ or Zn2+ 
content) and/or the release of Ca2+ from the endocytic compartments that drives the organellar 
fusion (161, 186, 214, 221, 270, 275). The recent characterization of TRPML1 activation by 
PI(3,5)P2 raised the possibility that this ion channel is activated by delivery to the PI(3,5)P2 rich 
lower portions of the endocytic pathway or that it is a proximity sensor for endocytic organelles 
(9, 270).  
TRPML3 is a close TRPML1 relative, which appears to be expressed in multiple 
endocytic vesicles including early endosomes and late endosomes. It is primarily expressed in 
the inner ear; the Varitint-waddler (Va) gain of function mutant of TRPML3 leads to massive 
degeneration of the hair cells causing deafness and a circling behavior phenotype (8, 20, 24-26, 
271, 276). TRPML1 and TRPML3 are contradirectionally regulated by pH (8, 23, 26), which is 
consistent with their proposed site of function: TRPML3 is inhibited by low pH typically present 
in the lower portion of the endocytic pathway. While acute deletion (or overexpression) of 
TRPML1 or TRPML3 has been shown to inhibit various aspects of endocytic function including 
autophagy (14, 162, 277-279), clear demarcation of their roles in endocytosis has not been 
established.  
TRPMLs are members of the TRP superfamily of ion channels, with which they share a 6 
transmembrane domain architecture, with a putative pore region located in between the 5th and 
6th transmembrane domains. TRPML1 contains a set of lysosomal targeting motifs whose 
deletion was shown to retain TRPML1 in the plasma membrane (271, 280). No localization 
signals have been shown for TRPML3 yet. Keeping in mind that transition metals have been 
shown to accumulate in the deeper portions of the endocytic pathway, we set out to establish 
whether or not they inhibit TRPMLs and whether this inhibition is a contributing factor to the 
 78 
transition metal effect on lysosomes. Here we report that some transition metals block the 
TRPML3 channel and that the block depends on cysteine residues in the vicinity of the channel’s 
pore. An “activating” mutation in TRPML3 and TRPML1, TRPML3A419P and TRPML1V432P, is 
insensitive to transition metal blockage. Metal toxicity appears to cause endocytic malfunction, 
indicated by the buildup of storage bodies. However, the inhibition of TRPMLs by transition 
metals does not seem to be the sole factor responsible for the lysosomal storage defects observed 
in these cells as inclusion profiles differ between these treatment.  
4.3 EXPERIMENTAL PROCEDURES 
Cell Culture: HeLa and HEK293 cells were maintained in DMEM (Sigma-Aldrich, St 
Louis, MO) supplemented with 7% FBS, 100 µg/mL penicillin/streptomycin, and 5 µg/mL 
Plasmocin prophylactic (Invivogen, San Diego, CA). For siRNA KD, antibiotic free media was 
used. Metals were added directly to the DMEM.  
siRNA-mediated KD: ON-TARGET plus siRNA were designed as described previously 
(162) and custom synthesized by Dharmacon (Lafayette, CO). The TRPML1 siRNA probe 
targeting the sequence 5'-CCCACATCCAGGAGTGTAA-3' in MCOLN1 was used for all 
TRPML1 KD. The TRPML3 siRNA probe targeting the sequence 5'-
CCAAUGGAUGACACAUAU-3' in MCOLN3 was used for TRPML3 KD. Non-targeting 
control siRNA#1 (Sigma) was used as a negative control. 6-well plates were transfected using 
Lipofectamine 2000 (Invitrogen, Carlsbag, CA). Transfections were performed as described by 
manufacturer’s protocol using 600 nM siRNA per well. All KDs were confirmed using SYBR-
green based quantitative real-time RT-PCR. 
 79 
Clones and mutagenesis. GFP-tagged TRPML1 and TRPML3 were obtained by cloning 
human TRPML1 and TRPML3 cDNA into pEGFP-N1 or pEGFP-C1 clones from Clontech 
(Mountain View, CA). TRPML3 clone was a gift from Shmuel Muallem (NIH, NIDCR). HA-
tagged constructs were obtained by cloning into pCMV-HA vector from Clontech. All clones 
were verified by sequencing through GENEWIZ (South Plainfield, NJ) using primers designed 
by Grace Colletti.  Site-directed mutagenesis was performed using the Gene TailorTM Site-
Directed Mutagenesis System from Invitrogen according to the manufacturer’s protocol.  
Electrophysiology: For conventional whole cell recording, cells were resuspended in 
DMEM and allowed to attach to a coverslip inside perfusion chamber. Transfected cells were 
identified by GFP fluorescence. Transmembrane currents were recorded using an HEKA EPC-10 
amplifier (HEKA Instruments, Southboro, MA), stored in a PC and analyzed using Patchmaster 
and Origin software. Currents were digitized at 1 kHz and filtered through low-bandpass filter 
set at 5 kHz cutoff frequency. In whole cell mode, the pipette solution contained (in mm) 140 
Cs-aspartate (to cancel endogenous K+ and Cl- conductances), 5 Na-ATP, 5 MgCl2, 10 HEPES, 
10 BAPTA, pH 7.2. The standard bath solution contained (in mm): 150 NaCl, 5 KCl, 1 CaCl2, 1 
MgCl2, 10 HEPES, pH 7.4. In some experiments, NaCl was replaced with NMDG-glutamate 
and 0 or 10 mm divalent metals were included in the bath solutions. The experiments were 
performed at room temperature. The solutions were applied by bath perfusion with ten volumes 
of the perfusion chamber. Pipette resistance was in the 2-8 MOhm range, and seal resistance was 
always over 1 GOhm. Series resistance and capacitance were compensated using the proprietary 
protocol included with Patchmaster. 
Electron Microscopy: Electron microscopy was performed as previously described (162). 
In brief, cells were fixed using 2.5% glutaraldehyde in 0.1M Na-cacodylate, washed with 0.1M 
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Na-cacodylate, postfixed with a solution containing 1% OsO4, washed with PBS, and stained en 
bloc for uranyl acetate. After dehydration in ethanol, the samples were resin embedded, mounted 
on grids and analyzed with a transmission electron microscope (100CX; JEOL Ltd). For 
colloidal gold uptake experiments, 10-nm gold particles were coated with gelatin and BSA. The 
particles were washed and added to the cells for 1 hr and chased for 6 hr to load the endocytic 
pathway and then fixed for conventional electron microscopy. The images were analysed and 
inclusions were counted using ImageJ.  
Statistical significance was calculated using a one-tailed, unpaired t-test with p≤0.05 
considered significant. Data are presented as mean±S.E.M. 
4.4 RESULTS 
4.4.1 TRPML3 is activated by PI(3,5)P2 
TRPML3 was previously shown to reside in the plasma membrane in overexpression 
systems (8, 20-26), therefore we performed whole cell patch clamp analysis to determine the 
dynamics of this channel. For these studies, we expressed GFP-fused human TRPML3 in HEK 
293 cells by transient cDNA transfection and tested its activity using whole cell patch clamp. In 
our system, we detected a fairly high rate of spontaneous wildtype TRPML3 activity: over 30% 
of cells (n=135) showed large inwardly rectifying currents characteristic of TRPML3 (Fig 4.1 
B). C- and N-terminal GFP fusion constructs showed the same tendency. Currents were recorded 
with Na+ and Ca2+ as main charge carriers, at pH 7.4. Mock transfected cells did not show this 
activity (data not shown, n=8). The incidence and amplitude of TRPML3 activity was 
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dramatically increased when 5 or 20 µM PI(3,5)P2 was included in the pipette solution (Fig 4.1). 
Some cells showed delayed activation of TRPML3 in the presence of PI(3,5)P2; the delay likely 
representing PI(3,5)P2 diffusion from the patch pipette into the cytoplasm (Fig 4.1C). The 
TRPML3 activation by PI(3,5)P2 is not entirely surprising since the putative PI(3,5)P2 binding 
motif previously identified in TRPML1 (9) is present in TRPML3 (TRPML1: 42RRR, 
55KFRAKGRK, TRPML3: 39RR, 52KFWARGRK).  
The functional significance of TRPML3 activation by PI(3,5)P2 is unclear. PI(3,5)P2 is 
believed to be restricted to the lower portions of the endocytic pathway, which is, ostensibly, 
outside or on the border of the TRPML3 functional range and localization. This is supported by 
the fact that wild type (WT) TRPML3, both spontaneously active and PI(3,5)P2 activated, is 
inhibited by low pH (Fig 4.1A). It’s possible that PI(3,5)P2 activation of TRPML3 via an 
increase in local concentration or proximity sensing could result in a calcium efflux that in turn 
initiates SNARE mediated fusion, as was suggested for TRPML1.  Fairly recent evolutionary 
separation between TRPML1 and TRPML3 (C elegans and Drosophila have only one mucolipin 
gene) could also suggest that at the present point of evolution, the functional specialization of 
these channels is at the stage of spatial segregation and may not (yet) involve specialization of 
signaling inputs.  
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Figure 4.1 TRPML3 activation by PI(3,5)P2. 
HEK 293 cells transfected with YFP-TRPML3 were analyzed using whole cell patch clamp with Na+ and Ca2+ as 
main charge carriers in the outside solution and Cs+ - in the pipette solution. A) Current voltage curve of TRPML3 
at different pH and presence/absence of PI(3,5)P2. Data represent 2 to 35 experiments. B) Bar graph representing 
probability of detecting TRPML3 activity in the presence and absence of PI(3,5)P2. Data represent 55 to 135 
experiments. C) Current recording illustrating development of TRPML3 current in cells perfused with PI(3,5)P2. 
Panel represents 10 to 14 experiments. 
 
Transfected HA- or GFP-tagged human TRPML1 did not produce currents in the 
presence or absence of PI(3,5)P2, at normal or low (4.5) pH (data not shown, n=13 and 31 
respectively). Furthermore, deletion of the putative TRPML1 localization signals (15LL and 
577LL), previously shown to result in retention of the channel in the plasma membrane (5, 6) did 
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not result in spontaneous or PI(3,5)P2 activated current activity under conditions of normal or 
low pH (data not shown, n=11 and 14 respectively).  Since previous studies had observed WT 
TRPML1 current with lysosomal patches under the same conditions, we suggest that additional 
factors are involved in TRPML1 activation by PI(3,5)P2 in the lysosomal context.  
4.4.2 TRPML3 is blocked by transition metals 
With the discovery of PI(3,5)P2 activation of TRPML3, our lab performed further 
analysis on transition metal block of TRPML3.  Addition of 1 to 100 µM of Co2+, Cu2+, Ni2+, 
Fe2+ and Zn2+ to the bath solution (corresponding to the lumen of endocytic organelles) inhibited 
both spontaneous and PI(3,5)P2 induced TRPML3 activity. The extent of inhibition varied 
between metals. Addition of 10-100uM of Cu2+ and Zn2+ consistently blocked the channel 
resulting in 70-90% inhibition at pH 7.4.  The same concentrations of Co2+ and Ni2+ also had a 
strong inhibitory effect, ~60-75% channel block, although the extent of this block varied 
between experiments (Fig 4.2A, B). Fe2+ was much less effective in blocking TRPML3 currents 
(Fig 4.2A, B).  
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Figure 4.2 TRPML3 block by transition metals. 
HEK 293 cells transfected with YFP-TRPML3 were analyzed using whole cell patch clamp with Na+ and Ca2+ as 
main change carriers in the outside solution and Cs+ - in the pipette solution. A) Representative current traces. B) 
Bar graph representing relative efficacy of each metal tested in blocking TRPML3. Data are expressed as percentage 
of total current lost after application of the given metal concentration. Data represent 3 to 10 experiments. 
 
The Va TRPML3 mutant A419P (TRPML3Va) was previously shown to be spontaneously 
active and to have reduced sensitivity to pH (8, 20, 24-26, 271). Fig 4.3A shows that this 
remained true in our system. The vast majority of cells expressing TRPML3Va (n=18/24) showed 
spontaneously active currents; the current development in the presence of PI(3,5)P2 described 
above for WT TRPML3 has not been detected in TRPML3Va expressing cells. TRPML3Va 
showed significantly reduced sensitivity to Co2+ and Cu2+; the efficacy of block fell to 
 85 
approximately 20% (n=6 and 4 respectively, Fig 4.3A,B,D). This is consistent with large 
structural changes introduced to these mutants by the helix-breaking proline residue, as 
suggested previously (8).  
The TRPML1 Va analogue, the V432P mutant, resulted in PI(3,5)P2 insensitive 
spontaneously active current which was potentiated by low pH and by removal of divalent 
cations (Fig 4.2C). It also showed little sensitivity to transition metals (Fig 4.2D). 
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Figure 4.3 The Va mutants and transition metals. 
HEK 293 cells transfected with YFP-TRPML3 were analyzed using whole cell patch clamp with Na+ and Ca2+ as 
main change carriers in the outside solution and Cs+ - in the pipette solution. A,B) Current voltage relationship and 
current traces demonstrating insensitivity of the Va TRPML3 mutant (A419P, TRPML3Va) to transition metals. C) 
Current trace showing potentiation of the Va TRPML1 (V432P, TRPML1Va) current by low pH and divalent free 
external buffer. Data on panels A-C represent 3 to 10 experiments. D) Bar graphs representing the efficacy of Co2+ 
and Cu2+ in blocking the TRPML1Va and the TRPML3Va. Please note significant loss of blocking efficacy compared 
to data on WT TRPML3 shown in Fig 2B. The loss of blocking efficiency in Va mutants was statistically significant 
(at p<0.05 level, when compared with WT) under all conditions. Data represent 4 to 6 experiments.  
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Cysteine residues were previously implicated in metallothionesins and their transcription 
factors to reduce metal toxicity and oxidative stress (281). In order to explore their role in 
TRPML3 block by transition metals, we substituted a cysteine near the pore of TRPML3 for 
serine: C450S. This mutation did not affect the TRPML3 current voltage curve (Fig 4.4A) and 
did not preclude TRPML3 gating by 20µM PI(3,5)P2 (75% activation n=32) (Fig 4.4B). 
However, it did significantly suppress the ability of Co2+ and Cu2+ to block TRPML3 (Fig 
4.4B,C). We conclude that C450 in TRPML3 is at least partially responsible for the block of 
TRPML3 by transition metals. No detectable activity was observed with the TRPML1 C436S 
mutant (n=6) suggesting that this mutant preserves the functional regulation of the WT 
TRPML1. 
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Figure 4.4 Cysteine residues in TRPML3 and block by transition metals. 
HEK 293 cells transfected with YFP-TRPML3 were analyzed using whole cell patch clamp with Na+ and Ca2+ as 
main change carriers in the outside solution and Cs+ - in the pipette solution. A) Current voltage relation of C450S 
TRPML3 current at normal and low pH. Note the loss of pH dependent TRPML3 inhibition with the cysteine 
mutant. B, C) Current traces and bar graph demonstrating decreased sensitivity of C450S TRPML3 to transition 
metals compared to WT TRPML3 (Fig 2). The loss of blocking efficiency in C450S mutants was statistically 
significant (at p<0.05 level, when compared with WT) under all conditions, except 100 µM Cu2+ (p=0.12). Data 
represent 2 to 10 experiments. PI(3,5)P2 was present in the pipette solution in these experiments. 
 
4.4.3 Significance of TRPML block by transition metals. 
TRPMLs are among many ion channels, transporters and enzymes active in the endocytic 
pathway. The biochemistry of transition metals in this pathway is far from being completely 
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understood. In order to delineate the impact of TRPML block on lysosomal function, we 
compared the types of storage bodies that accumulate in cells shortly after acute KD of TRPML1 
and TRPML3 and in cells treated with transition metals. If TRPML1 and TRPML3 block by 
transition metals is the sole cause of early lysosomal abnormalities induced by transition metals, 
then a) the ability of a metal to block TRPML would correlate with its ability to induce 
inclusions, and b) the types of storage bodies accumulating in metal treated and TRPML 
deficient cells would be the same.  
To test these assumptions, HeLa cells were treated with TRPML1 and TRPML3 specific 
siRNA for 24 to 72 h and TRPML1 and TRPML3 KD were verified by RT-PCR (Fig 4.5A). In a 
separate set of experiments utilizing microarray technology we observed little change in 
TRPML3 mRNA under the conditions of TRPML1 KD (116% and 107% of control levels; n=2). 
Previous reports estimated TRPML1 half-life in lysosomes to be several hours (6) and our 
previous experiments show that under the same conditions, TRPML1 protein is almost 
completely eliminated within 6 hours of transfection (162). Fig 4.5B shows that TRPML1 and 
TRPML3 KD resulted in a buildup of storage bodies similar to those seen in MLIV. Within 24 
hours of treatment, storage bodies began to accumulate in cells exposed to transition metals (Fig 
4.5C). Metal treated cells contained types of inclusion profiles that were scarcely observed in 
TRPML knockdown cells (Fig 4.5D).  Therefore, the block of TRPML channels by transition 
metals is not the sole cause of inclusion body formation in these cells.  However, that is not to 
say that block of these channels does not contribute to the formation of cellular inclusions and 
endocytic malfunction.  Preliminary data in our lab suggests that treatment of cells with 
transition metals or TRPML3 KD both lead to similar trafficking defects.  These findings further 
suggest that transition metal overload inhibits TRPML function, driving these endocytic defects.  
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Therefore, the differences we observe in storage bodies between TRPML KD and metal treated 
cells may be due to the fact that transition metals produce additional and compounding effects in 
addition to TRPML block, resulting in morphologically different inclusion profiles. 
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Figure 4.5 Ultrastructural comparison of TRPML KD and metal treated cells. 
A) Bar graph demonstrating siRNA efficacy of TRPML1 and TRPML3 KD in HeLa cells. B,C) Electron 
micrographs of HeLa cells treated for 24 hr with TRPML1 and TRPML3 siRNA (B) or with transition metals (C). 
Note accumulation of storage bodies under these conditions. D. Zoom in images of inclusions. 
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Close examination of storage bodies suggested 10 distinct types illustrated in Fig 4.6A. 
The inclusions are (or once were) parts of the endocytic pathway, since they could be loaded by 
the fluid phase marker BSA-conjugated colloidal gold (Fig 4.6B). Classifying the storage body 
types allowed us to calculate and compare inclusion indexes under various conditions.  
 
Figure 4.6 Inclusion types in metal treated and siRNA transfected HeLa cells. 
A) Representative inclusions of the 10 different cellular inclusion profiles observed in HeLa cells. B) Examples of 
inclusions loaded with colloidal gold. 
 
TRPML1 and TRPML3 KD resulted in accumulation of cytoplasmic inclusions in a time 
dependent manner, displaying essentially the same profiles of inclusions (Fig 4.7A,B). This 
result suggests that while TRPML1 and TRPML3 are likely distinct in their specific functions, 
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their loss has similar downstream targets and effects. Fig 4.7A shows that the total amount of 
inclusions accumulated in metal treated cells did not correlate with the severity of TRPML3 
block by these metals. Fig 4.2B shows that while Cu2+ and Zn2+ are similarly efficient in 
blocking TRPML3, Cu2+ is more effective than Zn2+ in causing inclusions. Furthermore, the 
inclusion profiles observed in metal treated and TRPML1/TRPML3 siRNA treated cells differed: 
the predominant type of inclusions in TRPML1 and TRPML3 KD cells was scarcely observed in 
metal treated cells (Fig 4.7B). We conclude that TRPML inhibition by transition metals is not the 
sole defining factor in the lysosomal aspects of transition metal toxicity.  
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Figure 4.7 Inclusion profiles in metal treated and TRPML siRNA transfected HeLa cells. 
A) The total number of inclusions per cell slice under different conditions. Metals were used at 100µM. Numbers 
below the bars represent conditions and number of cell slices used for analysis. Note that the number of inclusions in 
Cu2+ treated cells is much higher than the number of inclusion in Zn2+ treated cells, while Zn2+ and Cu2+ efficiency 
in blocking TRPML1 is about the same (Fig 2) B) Bar graph representing percentile value of each inclusion type in 
total number of inclusions per cell slice under different experimental conditions. Note that TRPML KD and metal 
treatments result in accumulation of different types of inclusions. 
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4.5 DISCUSSION 
Lysosomal digestive machinery is very complex in content and function. Its activity 
depends on a plethora of factors coordinating fusion and fission events, digestive enzymes and 
supporting proteins, metabolite transporters as well as ion channels, carriers and pumps 
responsible for proper ion balance and transmembrane ion release events. Here we have shown 
that one of the important components of the endocytic machinery – ion permeation through 
TRPML channels, is inhibited by transition metals. The inhibition seems to depend on a cysteine 
residue near the putative pore of the channels.  
Our data is in agreement with previously published studies that utilized the Va mutations 
in TRPML1 and TRPML3 but indicates that WT TRPML1 activity may depend on additional 
lysosomal factors for activation (8). The spontaneous, constitutive activity of the Va mutant 
channels and the role of the cysteine pore residue in transition metal permeability suggests that 
the Va mutation places the pore in an open state that blocks the full interaction of transition 
metals with the cysteine residue.  
The functional significance of TRPML block by transition metals remains to be 
established. Here we proposed that comparative analysis of storage bodies in TRPML deficient 
and metal treated cells as a test of whether or not the functional consequences of TRPML loss 
and metal treatment are the same. The fact that different inclusion profiles are seen in TRPML 
KD and metal treated cells suggests, especially since the profiles vary between metals, that, in 
addition to TRPML, transition metals affect other components of the endocytic pathway. 
Comparison of the inclusion profiles in TRPML KD cells and in cells treated with transition 
metals indicates that both treatments result in the buildup of storage bodies, however their 
composition varies. Also, these data suggest that although transition metal buildup in TRPML 
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KD cells may contribute to disease pathology or substrate buildup, it is not the sole cause of 
inclusion body formation in these cells. A detailed investigation of the effects of transition 
metals on specific components of lysosomal digestive machinery, including TRPML channels 
will help elucidate their place in the lysosomal aspects of transition metal toxicity.  
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
This work spans several aspects of TRPML1 function.  The major focus of my work has 
been to understand the protein and transcriptional changes caused by TRPML1 loss in order to 
delineate cell death and inflammatory pathways that may be activated in MLIV.  Such studies 
may provide valuable information for understanding the primary downstream effects caused by 
TRPML1 loss, as well as providing insight into properly treating this disorder.  Below is a 
summary of this work, illustrated in Figure 5.1. 
TRPML1 loss leads to both protein and transcriptional changes.  At the lysosomal level, 
TRPML1 loss specifically results in CatB and LAMP1 increase, as well as a decrease in LAL.   
The increase in CatB seems to be caused by decreased secretion (Fig 5.1.1.), and was not altered 
at the transcriptional or translational levels.  Whether these are the only lysosomal changes will 
need to be further evaluated.  One method to do this would be to compare lysosomal protein 
profiles using a 2-D DIGE analysis, comparing control and TRPML1 KD cells.  I attempted this 
method, successfully isolating and analyzing lysosomal fractions; however, the analysis 
identified several non-lysosomal components.  Therefore, this method will need to be revised in 
the future, possibly by using a more stringent lysosomal isolation protocol as well as collecting 
cells grown in low-serum media, in order to limit the amount of background substrates. 
From our protein analysis, we found that CatB is released into the cytosol of TRPML1 
KD cells as seen in Figure 5.1.2.  This leak is accompanied by an increase in CatB and Bax 
 98 
dependent apoptosis (Fig 5.1.4, 5).  Furthermore, inhibition of Bax did not significantly decrease 
cytosolic CatB levels suggesting that Bax activation is downstream of CatB release.  Apoptosis 
was measured using a Caspase-3 activity assay.  Future work will focus on elucidating these cell 
death pathways.  Preliminary Western blot and fluorogenic data (not shown) suggests that 
Caspase-9 and Caspase-8 are not activated by TRPML1 KD, while cytochrome C is released 
from the mitochondria.  Previous studies have shown that during the induction of apoptosis, Bid 
can translocate from the cytoplasm to the mitochondria and bind Bax, resulting in a 
conformation change which induces insertion of Bax into the outer mitochondrial membrane and 
release of cytochrome C.  This process has been shown to be caspase independent and cathepsin 
dependent (158, 282).  It has also been shown that Bax can activate p53-driven cell death 
pathways independent of caspase activity.  In this study, Caspase-3 was still activated but was 
not contributing to p53-driven cell death, demonstrating that multiple cell death pathways can 
occur simultaneously (283).  Therefore identifying whether Caspase-3 is activated downstream 
of Bax activation and cytochrome C release will help clarify TRPML1 mediated apoptosis.  For 
example, we will test whether CatB inhibition blots Bax activation and whether Bax inhibition 
prevents cytochrome C release in TRPML1 KD cells.  Since we see Caspase-3 activation in our 
cells, which appears to be independent of Caspase-8 and Caspase-9, we can also test whether p53 
is activated in these cells.  Another possibility, is that Bax and Cathepsin B are functioning in 
separate pathways.  One study found that Cathepsin driven apoptosis functioned independently 
of Bid, suggesting that the Bid/Bax pathway and Cathepsin-mediated apoptosis may play a role 
in two separate pathways (284).  Therefore, we will also evaluate alternative routes of cell death 
in our TRPML1 KD, such as necrosis.  It may be possible that multiple pathways are 
simultaneously being activated in these cells.  One interestingly possibility, given that TRPML1 
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is suggested to be an Fe2+ release channel (161), is that a buildup of Fe2+, which has been shown 
to drive lysosomal ROS production and cause lysosomal permeabilization (285), could be 
driving this pathway.   
The changes we observe in CatB, LAMP1, and LAL (members of the “CLEAR” network 
of lysosomal genes) in our TRPML1 KD are independent of transcriptional changes.  This 
suggests that the “CLEAR” network may be activated by greater amounts of endocytic stress, not 
seen in the early stages of TRPML1 loss.  Interestingly, through our microarray analyses, we saw 
consistent changes in non-lysosomal genes outside of the “CLEAR” network.  Preliminary 
analysis showed that the p50/p105 subunit of NFκB was associated with a large percentage of 
these genes and was upregulated (~20-40%) after TRPML1 KD.  Further analysis showed that 
these changes resulted in increased p50 protein levels as well as nuclear translocation of this 
transcription factor as modeled in Figure 5.1.7.  These changes appear to be independent of CatB 
release.  An interesting observation made in previous studies links NFκB to pro-inflammatory 
responses, such as those seen in MLIV and other LSDs.  This suggests that NFκB upregulation in 
response to TRPML1 loss may drive these inflammatory responses (Fig 5.1.8), which may 
modulate the pathogenesis of MLIV (Fig 5.1.9).  Further work will need to be done to determine 
if NFκB is contributing to the inflammatory responses seen in this disease. 
Delineating the p50 NFκB pathway in TRPML1 KD cells will be the focus of future 
work in the lab.  Analysis of candidate genes after NFκB modulation will confirm whether this 
transcription factor is suppressing or activating these genes.  Furthermore, elucidating the 
pathways that result in NFκB upregulation may help us dissect the early steps of TRPML1 KD.  
Preliminary results suggest that CatB release may be linked to NFκB upregulation, as CatB KD 
inhibited NFκB increase (data not shown).  Caspase-1, a known substrate of CatB and an 
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activator of the NFκB pathway, was not activated in our KD cells.  However, NFκB regulation is 
a complex pathway, which can be modulated by several inputs; therefore a more detailed 
analysis of its activation as well as downstream effects will be the target of future work in the 
lab. 
These data demonstrate that the immediate effects of TRPML1 loss result in dynamic and 
complex cellular changes, which may modulate cell death.  These studies are the first to address 
the early stages of TRPML1 loss, in the context of cell death.  Studies focused on these early 
events will hopefully clarify the primary defects of MLIV, driving a better understanding of both 
endocytic function and how to treat lysosomal disorders arising from non-enzymatic protein loss. 
 
Figure 5.1 Model representing changes in TRPML1 KD cells and how these may contribute to cellular 
malfunction. 
TRPML1 KD or loss of another lysosomal component results in lysosomal alterations (1) such as impaired 
secretion, fusion or enzymatic activity, leading to the appearance of storage bodies (3). The buildup and release of 
lysosomal enzymes such as CatB into the cytosol due to lysosomal permeabilization (2) results in cleavage of 
proapoptotic factors (4-5). In response to TRPML1 KD, NFκB levels are upregulated (7) by an unknown mechanism 
either in direct response to TRPML1 KD or in response to altered lysosomal integrity (6). Changes in TF activity 
and levels may result in cellular changes such as activation of inflammatory responses (8) and could contribute, 
alleviate, or exacerbate apoptotic activation (9) leading to cell death (10).  
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 The remainder of my work was focused on characterizing the function and activity of 
TRPML channels.  Due to the lack of TRPML1 expression at the plasma membrane, even under 
overexpressing conditions, we focused our work on TRPML3, the closely related relative.  I 
performed the preliminary work using patch clamp analysis, studying TRPML3 block by 
transition metals, activity of the constitutively active TRPMLVa mutants, and analyzing the 
activity of TRPML3 mutants in order to identify key residues that regulate TRPML3 activity 
(discussed in Appendix B).  This project was taken over by several members of the lab, who 
completed the patch clamp analysis and electron microscopy profiling of TRPML3.  Our work is 
in agreement with previously published papers, which analyzed TRPML function, and provide a 
unique profiling of transition metal blockage of these channels.   
 Interestingly, our patch clamp analysis as well as similarities between TRPML1 and 
TRPML3 KD (discussed in Appendix B), suggest that there may be similarities shared between 
these channels.  However, the localization of these channels suggests that they may function in 
mutually exclusive cellular compartments.  In support of this, TRPML1 does not localize to the 
plasma membrane, as does TRPML3.  Furthermore, a dileucine mutation, which targets 
TRPML1 to the plasma membrane, is not active in our system, suggesting that it requires 
localization to the lysosome (likely due to PI(3,5)P2 and possibly other adaptor proteins present 
at the lysosome) for proper function.  Taken together, our data suggest that TRPML channels 
share similar activity profiles; however they have evolved to work in specific environments, 
which likely drive their specific cellular functions. 
 My work will add a new level of understanding to MLIV research, providing a clearer 
depiction of cell death caused by TRPML1 loss as well as characterizing TRPML1 function and 
its relationship to TRPML3.  These studies also leave several questions unanswered, which will 
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be addressed in the future by the Kiselyov Lab.  For example: what is the role of NFκB in 
TRPML1 loss, do the changes we see modulate disease pathology, and do TRPML1 and 
TRPML3 play redundant roles in the endocytic pathway?  These few examples point, I think, to 
the major direction of this project, which will be dissecting the pathways activated by TRPML1 
loss in order to elucidate the context of TRPML1 function and how the cell senses/responds to its 
loss.  It is clear that our knowledge of the endocytic pathway and its complexity is ever growing; 
therefore, using defects in this pathway as a tool to study its function is a major driving force to 
understanding the pathway.  This novel approach to studying the immediate effects of LSD 
pathogenesis may open a new system to study the endocytic pathway and reveal cellular 
dynamics that we were previously unaware of.   
  
6.0   
7.0  PPENDIXES 
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APPENDIX A 
A.1 MICROARRAY GENE CANDIDATES 
Table.A.1 Gene candidates from TRPML1 KD microarray  
 Gene Description 
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 ANAPC13 Homo sapiens anaphase promoting complex subunit 13 (ANAPC13). 
CIRBP Homo sapiens cold inducible RNA binding protein (CIRBP). 
HNRPH2 Homo sapiens heterogeneous nuclear ribonucleoprotein H2 (H') (HNRPH2), transcript variant 1. 
MGC24039 Homo sapiens hypothetical protein MGC24039 (MGC24039). 
RDH10 Homo sapiens retinol dehydrogenase 10 (all-trans) (RDH10). 
RPL15 Homo sapiens ribosomal protein L15 (RPL15). 
SNCG Homo sapiens synuclein, gamma (breast cancer-specific protein 1) (SNCG). 
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BCAR3 Homo sapiens breast cancer anti-estrogen resistance 3 (BCAR3). 
BIVM Homo sapiens basic, immunoglobulin-like variable motif containing (BIVM). 
CAP2 Homo sapiens CAP, adenylate cyclase-associated protein, 2 (yeast) (CAP2). 
CPLX1 Homo sapiens complexin 1 (CPLX1). 
ERO1L Homo sapiens ERO1-like (S. cerevisiae) (ERO1L). 
GDAP1 Homo sapiens ganglioside-induced differentiation-associated protein 1 (GDAP1), transcript variant 1. 
HCN3 Homo sapiens hyperpolarization activated cyclic nucleotide-gated potassium channel 3 (HCN3). 
IRAK2 Homo sapiens interleukin-1 receptor-associated kinase 2 (IRAK2). 
KRT17 Homo sapiens keratin 17 (KRT17). 
KRT80 Homo sapiens keratin 80 (KRT80), transcript variant 1. 
MAL2 Homo sapiens mal, T-cell differentiation protein 2 (MAL2). 
PAQR4 Homo sapiens progestin and adipoQ receptor family member IV (PAQR4). 
PTBP2 Homo sapiens polypyrimidine tract binding protein 2 (PTBP2). 
PTPLB Homo sapiens protein tyrosine phosphatase-like (proline instead of catalytic arginine), member b (PTPLB). 
QSOX2 Homo sapiens quiescin Q6 sulfhydryl oxidase 2 (QSOX2). 
RAI14 Homo sapiens retinoic acid induced 14 (RAI14). 
SCG2 Homo sapiens secretogranin II (chromogranin C) (SCG2). 
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SIX4 Homo sapiens SIX homeobox 4 (SIX4). 
SLC2A3 Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 3 (SLC2A3). 
SLC25A19 Homo sapiens solute carrier family 25, member 19, nuclear gene encoding mitochondrial protein. 
SNAP25 Homo sapiens synaptosomal-associated protein, 25kDa (SNAP25), transcript variant 2. 
SOCS2 Homo sapiens suppressor of cytokine signaling 2 (SOCS2). 
TMEM145 Homo sapiens transmembrane protein 145 (TMEM145). 
VGF Homo sapiens VGF nerve growth factor inducible (VGF). 
WDR22 Homo sapiens WD repeat domain 22 (WDR22). 
 
Table A.2  Gene candidates for PPT1 KD microarray 
Gene Description Gene Description 
LOC100129882 PREDICTED: Homo sapiens similar to 
mCG49427 (LOC100129882) KRT17 Homo sapiens keratin 17 (KRT17). 
MORF4L1 
 
Homo sapiens mortality factor 4 like 1 
(MORF4L1), transcript variant 2. 
 
KRT17P3 PREDICTED: Homo sapiens misc_RNA (KRT17P3), miscRNA. 
ALS2CR4 
Amyotrophic lateral sclerosis 2 chromosome 
region, candidate 4, variant 1. 
 
KRTCAP2 Homo sapiens keratinocyte associated protein 2 (KRTCAP2). 
ANG 
Homo sapiens angiogenin, ribonuclease, RNase 
A family, 5 (ANG), variant 2. 
 
LOC100132377 PREDICTED: Homo sapiens hypothetical protein LOC100132377. 
ANXA2 
Homo sapiens annexin A2 (ANXA2), transcript 
variant 1. 
 
LOC645638 PREDICTED: Homo sapiens misc_RNA (LOC645638), miscRNA. 
ANXA2P1 
Homo sapiens annexin A2 pseudogene 1 
(ANXA2P1) on chromosome 4. 
 
LOX Homo sapiens lysyl oxidase (LOX). 
ANXA3 Homo sapiens annexin A3 (ANXA3).  LPP 
Homo sapiens LIM domain containing preferred translocation partner in 
lipoma (LPP). 
ARMET Homo sapiens arginine-rich, mutated in early stage tumors (ARMET). MGC4677 
Homo sapiens oxidized low density lipoprotein (lectin-like) receptor 1 
(OLR1). 
ARNT2 Homo sapiens aryl-hydrocarbon receptor nuclear translocator 2 (ARNT2). MRLC2 Homo sapiens protein disulfide isomerase family A, member 5 (PDIA5). 
ARPC1A Homo sapiens actin related protein 2/3 complex, subunit 1A, 41kDa (ARPC1A). NAMPT Homo sapiens protein disulfide isomerase family A, member 6 (PDIA6). 
ASNS Homo sapiens asparagine synthetase (ASNS), transcript variant 1. NFIB 
Homo sapiens SCO cytochrome oxidase deficient homolog 1 (yeast) 
(SCO1), nuclear gene encoding mitochondrial protein. 
C1GALT1C1 C1GALT1-specific chaperone 1 (C1GALT1C1), transcript variant 1. NIPA1 Homo sapiens stromal cell-derived factor 2-like 1 (SDF2L1). 
 105 
C1ORF218 Homo sapiens chromosome 1 open reading frame 218 (C1orf218). NPC1 Homo sapiens SEC11 homolog C (S. cerevisiae) (SEC11C). 
CAV2 Homo sapiens caveolin 2 (CAV2), transcript variant 1. NT5E Homo sapiens sel-1 suppressor of lin-12-like 3 (C. elegans) (SEL1L3). 
CCL5 Homo sapiens chemokine (C-C motif) ligand 5 (CCL5). OLR1 Homo sapiens hypothetical protein MGC4677 (MGC4677). 
CD46 CD46 molecule, complement regulatory protein (CD46), transcript variant m. PDIA5 Homo sapiens myosin regulatory light chain MRLC2 (MRLC2). 
CFB Homo sapiens complement factor B (CFB). PDIA6 Homo sapiens nicotinamide phosphoribosyltransferase (NAMPT). 
CLDN12 Homo sapiens claudin 12 (CLDN12). SCO1 Homo sapiens nuclear factor I/B (NFIB). 
CPOX Homo sapiens coproporphyrinogen oxidase (CPOX). SDF2L1 
Homo sapiens non imprinted in Prader-Willi/Angelman syndrome 1 
(NIPA1). 
CREG1 Homo sapiens cellular repressor of E1A-stimulated genes 1 (CREG1). SEC11C Homo sapiens Niemann-Pick disease, type C1 (NPC1). 
CRELD2 Homo sapiens cysteine-rich with EGF-like domains 2 (CRELD2). SEL1L3 Homo sapiens 5'-nucleotidase, ecto (CD73) (NT5E). 
CXORF61 Homo sapiens chromosome X open reading frame 61 (CXorf61). SLC2A3 
Homo sapiens oxidized low density lipoprotein (lectin-like) receptor 1 
(OLR1). 
CYR61 Homo sapiens cysteine-rich, angiogenic inducer, 61 (CYR61). SLCO4A1 Homo sapiens protein disulfide isomerase family A, member 5 (PDIA5). 
DNAJB11 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, member 11 (DNAJB11). SOD2 Homo sapiens protein disulfide isomerase family A, member 6 (PDIA6). 
DUSP1 Homo sapiens dual specificity phosphatase 1 (DUSP1). SPCS3 
Homo sapiens SCO cytochrome oxidase deficient homolog 1 (yeast) 
(SCO1), nuclear gene encoding mitochondrial protein. 
EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1), variant 2. SRGN Homo sapiens stromal cell-derived factor 2-like 1 (SDF2L1). 
EFHD2 Homo sapiens EF-hand domain family, member D2 (EFHD2). SSR1 Homo sapiens SEC11 homolog C (S. cerevisiae) (SEC11C). 
EFR3A Homo sapiens EFR3 homolog A (S. cerevisiae) (EFR3A). TMBIM6 Homo sapiens sel-1 suppressor of lin-12-like 3 (C. elegans) (SEL1L3). 
FAM46A Homo sapiens family with sequence similarity 46, member A (FAM46A). TNFRSF12A 
Homo sapiens solute carrier family 2 (facilitated glucose transporter), 
member 3 (SLC2A3). 
GOLT1B Homo sapiens golgi transport 1 homolog B (S. cerevisiae) (GOLT1B). TROVE2 
Homo sapiens solute carrier organic anion transporter family, member 
4A1 (SLCO4A1). 
HS.127310 Homo sapiens cDNA DKFZp434C1613 (from clone DKFZp434C1613) TXNDC12 
Superoxide dismutase 2, mitochondrial (SOD2), nuclear gene encoding 
mitochondrial protein, transcript variant 1. 
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HS.570988 Homo sapiens primary neuroblastoma cDNA, clone:Nbla10111, full insert sequence UBE2V2 
Homo sapiens signal peptidase complex subunit 3 homolog (S. 
cerevisiae) (SPCS3). 
HS.5724 Homo sapiens cDNA DKFZp779O0231 VTN Homo sapiens serglycin (SRGN). 
IER3 Homo sapiens immediate early response 3 (IER3). WFDC1 
Homo sapiens signal sequence receptor, alpha (translocon-associated 
protein alpha) (SSR1). 
JUN Homo sapiens jun oncogene (JUN). ZFP36 Homo sapiens transmembrane BAX inhibitor motif containing 6 (TMBIM6), transcript variant 1. 
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APPENDIX B 
B.1 PRELIMINARY ANALYSIS OF THE CLOSELY RELATED ENDOSOMAL 
CHANNEL TRPML3 
  
TRPML3 is a closely related homologue of TRPML1, with similar proposed topology 
and localization to late endocytic vesicles.  A mutation in the gene MCOLN3, coding for 
TRPML3, results in the varitint-waddler phenotype in mice, characterized by pigmentation, 
hearing and behavioral defects (8, 276, 286, 287).  The equivalent mutation in TRPML1 results 
in a constitutively active channel with the same activity and ion selectivity as TRPML3, 
suggesting that these channels may function similarly (8).  Furthermore, localization studies of 
these channels also suggest that TRPML1, TRPML2, and TRPML3 colocalize in vesicles in the 
later portion of the endocytic pathway and were shown to homo- and heterotetramize (288).  
Although little is known about the role and regulation of TRPML3, it has been suggested to play 
a role in endocytic trafficking, Ca2+ conductance from the endocytic organelles (289), and to be a 
regulator of late endocytic pH (290).  Therefore, we believe TRPML3 could a useful tool for 
comparative analysis with TRPML1 and suggest that if these channels share similar function or 
activity, that loss of either mucolipin could result in similar phenotypes and cellular responses.  
To test the similarity between TRPML1 and TRPML3, we performed structure/function analysis 
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of TRPML3 using site-directed mutagenesis followed by patch clamp analysis.  We found that, 
consistent with other reports, TRPML3 seems to share an activity profile similar to TRPML1, 
although it is inhibited by low pH, unlike TRPML1 (Fig 4.1A).  Furthermore, 48 hour KD of 
TRPML3 resulted in a similar cellular inclusion phenotype and lysosomal protein changes seen 
in TRPML1.  This preliminary work suggests that these channels not only share similar activity 
and inhibition profiles, but also that the loss of these channels shares similar pathologies.  This 
may lead to a better understanding as to the celular role of these channels as well as the 
consequence of their downregulation. 
 
B.1.1 Mutation of conserved TRPML residues result in inactivation of TRPML3 
The following sections include patch clamp analysis, to determine the activity of 
TRPML3 and its block by transition metals.  The structure/function analysis consisted of site-
directed mutagenesis of key residues that may play a role in the activity and regulation of this 
channel followed by analysis of mutant channel activity.  During these studies several of these 
mutations were concurrently identified by another group, verifying our results.  However we also 
identified other key residues which may contribute to the activity of TRPML channels.  The 
activating mutations discussed in section 4.4 were also published during these studies, and 
therefore we made these mutants to test pore selectivity of these mutants to Cu2+.  The following 
section describes the outcomes of these experiments.    
Structure/functional analyses performed on the Shaker family of K+ channels identified 
critical residues in the voltage sensing domains of these channels (transmembrane domains) 
which control the opening and closing of the pore through interaction with key residues in linker 
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regions of the channel (291, 292).  Using these studies as a guide, we targeted several charged 
residues in the pore, linker regions, and 4th transmembrane domain of TRPML channels.  By 
aligning the highly homologous TRPML1 and TRPML3, we identified several conserved 
residues in these regions.  Using site-directed mutagenesis, we negated or reversed the charge of 
the pore residues D458 and D459 as well as the S3/TM4 residues E336/N339, and E349.  These 
mutants were screened for proper lysosomal localization in HeLa cells.  Properly localized 
mutants were then transfected in HEK293 cells and activity was measured using whole-cell 
patch clamp analysis as described in section 4.  Several additional pore, C-terminal, and S4 
residues were also screened, but they either resulted in ER retention or did not alter TRPML3 
activity (data not shown).     
Negating the charge of D458 and D459 resulted in a small, linear current as seen in 
Figure B.1.A.  This current remained unaltered after the addition of Cu2+.  This suggests that 
these pore residues play a critical role in regulating the activity of the channel and may 
coordinate the movement of cations ions through the channel.  A study published in 2007 
demonstrates that switching these acidic amino acids to basic residues (DDKK) eliminates the 
inwardly rectifying current of TRPML3, confirming our results (8). 
Further analysis outside of the pore region suggests that residues in the S3 and TM4 
domain of TRPML3 regulate the activity of the pore region.  Switching the charge in residues 
E446/N339 and E469 resulting in the loss of an inwardly rectifying current.  This may suggest 
that these residues coordinate the opening and closing of the pore, as seen in Figure B.1.B.  The 
residues targeted in both regions are conserved between TRPML1 and TRPML3, suggesting that 
these residues may play a similar function between these channels.  This evidence points to the 
similarity between TRPML channels. 
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Figure B.1 Analysis of mutants reveals inactivating mutations in the pore and S3 domains of TRPML3.  
HEK293 cells were transfected with GFP-TRPML3 and analyzed using whole cell patch clamp with Na+ and Ca2+ as 
main charge carriers in the outside solution and Cs+ in the pipette solution. A) Mutations made in the pore domain of 
TRPML3 result in small, linear currents. Ablating the charge of residues D458 and D459 both resulted in 
inactivation of the inwardly rectifying current.  B) Current voltage relationship demonstrating the loss of inward 
current by changing or ablating the charge of E349 or double mutants E336/N339 in the TM4/S3 domain of the 
TRPML3. 
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B.1.2 Activating mutations in the S3 domain of TRPML1 and TRPML3 are not sensitive 
to Cu2+ block. 
When the activating mutation in the S3 domain of TRPML3 and TRPML1 was identified 
in 2007, it provided a useful tool for studying these channels.  First, it allowed us to determine if 
“fixing” the channel in an open state allowed the passage of transition metals.  Furthermore, it 
was shown that this TRPML1 mutant localized to the plasma membrane and produced 
spontaneous activity, allowing us to analyze it using patch clamp analysis.  The following data is 
the preliminary work from section 4.   
TRPML3A419P resulted in spontaneous channel activity (100% of patches resulted in large 
inward rectifying current).  Furthermore, addition of various concentrations of Cu2+, previously 
shown to robustly inhibit TRPML3 activity, did not inhibit the channel as seen in Figure B.2.A.  
Analysis of TRPML1V432P also resulted in spontaneous inward rectifying current.  Addition of 
Cu2+ did not inhibit this channel, suggesting that these channels have similar inwardly rectifying 
currents and that the coordination of transition metal block may be shared between these 
channels.  Another study demonstrated that patching enlarged lysosomes, transfected with 
wildtype TRPML1, resulted in inwardly rectifying current, further supporting that this is the 
endogenous activity of this channel (9).  The similar activity profiles of these channels, 
combined with the effects of mutating conserved residues suggests that these channels may have 
similar activity profiles, while functioning in separate components of the endocytic pathway.   
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Figure B.2 Sensitivity of Va TRPML3 and TRPML1 mutants to Cu2+ 
HEK293 cells were transfected with GFP-TRPML3 and analyzed using whole cell patch clamp with Na+ and Ca2+ as 
main charge carriers in the outside solution and Cs+ in the pipette solution. A) Current voltage relationship 
demonstrating insensitivity of the Va TRPML3A419 mutant to transition metals. Inhibition of wildtype TRPML3 and 
TRPML3A419 is graphed (n=4) B) Current voltage relationship demonstrating inward current and insensitivity of the 
Va TRPML1V432P mutant to transition metals.     
 
B.1.3 TRPML3 KD leads to similar cellular pathologies as TRPML1 KD 
In order to compare the effects of TRPML3 KD to TRPML1 KD, we performed a 48 
hour KD using transient transfection with TRPML3 targeting siRNA.  We verified KD using 
qRT-PCR as described in section 2.  As seen in Figure B.3.A, KD resulted in a 63.3%±9.2 
decrease in MCOLN3 mRNA levels compared to control cells (n=3, p<.01).  To determine if 
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TRPML3 KD had the same effects on lysosomal components as TRPML1 KD, we used Western 
blot analysis to measure mature CatB and LAL levels in these KD cells.  As seen in Figure 
B.3.B, TRPML3 KD leads to a similar increase in CatB and decrease in LAL, as seen in 
TRPML1 KD cells.  This suggests that although these proteins may function in separate 
compartments of the cell, that loss of these proteins may activate similar responses.   
Finally, we analyzed cellular inclusion formation in TRPML3 KD cells using electron 
microscopy.  As seen in Figure B.3.C., TRPML3 lead to a similar increase in inclusion formation 
as TRPML1, suggesting that loss of this protein results in endocytic malfunction.  A further 
profiling of these inclusions will elucidate whether these bodies share similar phenotypes.   
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Figure B.3. TRPML3 KD results in similar cellular changes as TRPML1 KD 
A) 48 hour siRNA mediated KD of TRPML3 resulted in decreased MCOLN3 mRNA levels (n=3, *p<.01).  B)  
Western blot analysis shows an elevation of mature CatB and a decrease in LAL 48 hours after TRPML1 and 
TRPML3 KD.  C)  Electron microscopy shows a similar buildup of storage inclusions 48 hours after TRPML1 and 
TRPML3 KD.  
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B.1.4 Conclusions and acknowledgements 
Our data strongly support the hypothesis that TRPML1 and TRPML3 function similarly, 
although in different cellular compartments.  It is interesting that loss of either channel results in 
similar cellular changes.  It is important to note an observation as well about the activating Va 
mutants of each channel:  under overexpression conditions, these activating channels lead to 
severe cell death and thus were difficult to patch.  This suggests that the regulation of channel 
activity is critical for cell survival, and may suggest why no gain of function mutations have 
been linked to disease.   
Whether these channels play redundant roles in the cell or whether the loss of one can be 
compensated to some extent by the other will still need to be evaluated.  It seems that these 
channels do share similarities, but it may be their spatial differences that lead to their specific 
cellular functions.  In the future it will be interesting to test whether overexpression of either 
channel can rescue the downregulation of the other.  Furthermore, understanding the localization 
differences between these channels and further elucidating their roles in endocytic compartments 
will be critical for clarifying the role of these channels in endocytic function. 
For these studies I would like to thank Christopher Lyons for imaging and counting the 
cellular inclusions in TRPML1 and TRPML3 cells compared to control cells.  I would also like 
to thank my undergraduate Emina Hodzic for help in creating and screening TRPML3 mutant 
channels.   
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